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Background.  Carbapenem-resistant Enterobacteriaceae (CRE) and other carbapenem-resistant 
organisms (CROs) pose urgent challenges to patient care. These bacteria are highly drug-
resistant and are associated with significant attributable mortality. Current prevention 
strategies in United States (U.S.) healthcare facilities aim to reduce selective pressure from 
antibiotic exposure and to reduce patient-to-patient spread. These efforts are hampered by a 
lack of rapid and cost-effective diagnostics to identify these organisms. These diagnostic 
challenges leave basic epidemiological questions unanswered, including how many and which 
types of U.S. inpatients are asymptomatic carriers.  
 
Objectives.  We aimed to measure the prevalence of, and risk factors for, CRO colonization 
among high-risk U.S. hospitalized patients and to develop statistical and machine learning 
prediction models that could help to address existing diagnostic limitations. 
 
Methods.  To achieve these aims, we developed two study cohorts. The first, a one-year 
prospective cohort of Johns Hopkins Hospital (JHH) intensive care unit patients, screened 
patients for CRO carriage at unit admission. Isolates were speciated and molecularly 
characterized, and pre-admission exposure data were used to evaluate colonization risk factors 
and to develop predictive models of colonization with machine learning methodologies (Aim 1). 




clinical decision tree (Aim 2) and a risk score (Aim 3) to predict whether infections were 
extended-spectrum B-lactamase (ESBL)-producing. ESBLs confer resistance to most antibiotics 
except carbapenems, and rapid identification can reduce unnecessary carbapenem 
administration. Through the lens of this real-world example, we methodologically compared 
these two prediction approaches (Aim 3). 
  
Results.  Aim 1 included 3,327 unit visits and 2,878 (87%) admission swabs. Our study found 
that 7.5% of patients were perirectally colonized with CROs and identified high organism and 
resistance mechanism diversity. Many variables were significantly associated with carriage, but 
resulting models were not highly predictive. Aims 2 and 3 analyzed 1,288 bacteremic patients 
and yielded higher performing prediction models for ESBL infection. We found that decision 
trees and risk scores performed similarly in our case study, but they offered different strengths 
and limitations. 
 
Conclusions.  Statistical and machine learning prediction models offer an important 
complement to microbiological diagnostics. They can circumvent existing resource and practical 
constraints, but high biological heterogeneity can compromise their performance. Increasing 
familiarity with these methods, as well as refining distinctions between causal inference and 
prediction, may improve statistical tools for identifying colonization or infection with CROs and 
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1.1. MultiDrug-Resistant Gram-Negative Bacteria in United States (U.S.) Healthcare Settings 
 
Healthcare-associated infections (HAIs) represent a significant patient safety threat. Each day in 
United States (U.S.) hospitals, one of every 25 patients experiences an HAI [1], causing more 
than 90,000 patient deaths per year and in excess of $20 billion in direct healthcare costs [2]. 
Many of these infections are due to multidrug-resistant (MDR) bacteria, which patients can 
acquire from healthcare exposure, e.g., in a hospital, through multiple routes: environmental or 
medical device/equipment contamination, healthcare worker-mediated transmission, and/or 
direct contact with other patients [3].  
 
Promisingly, in the last 15 years HAI rates due to MDR Gram-positive bacteria (e.g., methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE)) have 
stabilized or declined in many healthcare populations and settings [4-6]. During this same time 
period, however, the threat from MDR Gram-negative (MDRGN) bacteria has increased. Of 
particular concern are carbapenem-resistant Enterobacteriaceae (CRE) and other carbapenem-
resistant organisms (CROs), which are resistant to almost all commonly used antibiotics and can 
impose attributable mortality rates approaching 50 percent [7]. Informally termed the 
“Nightmare Bacteria” [8], CRE have been designated as one of only three urgent antibacterial 
threats by the U.S. Centers for Disease Control and Prevention (CDC), due to their increasing 




Although still rare in the U.S., with a crude incidence of approximately 3 infections per 100,000 
U.S. residents, the domestic incidence of CRE has more than tripled in the last 15 years [10].  
 
1.2. Carbapenem-Resistant Organisms (CROs) 
1.2.A. Carbapenem-Resistant Enterobacteriaceae (CRE) 
 
Enterobacteriaceae are a large family of Gram-negative bacteria that colonize the 
gastrointestinal (GI) tract of humans and animals (Figure 1.1) [11-13]. Enterobacteriaceae 
spread relatively easily among humans, including via environmental, food, and hand carriage 
routes [14]. Many Enterobacteriaceae species comprise important nosocomial pathogens, 
including Escherichia coli, Klebsiella spp., and Enterobacter spp. Although patients naturally 
carry, i.e., are colonized with, antibiotic-susceptible Enterobacteriaceae in their GI tracts, 
clinical (i.e., symptomatic) infections can occur in any body site, particularly the urinary tract or 
bloodstream [15]. 
 
The carbapenem antibacterial class includes four antibiotics: imipenem, meropenem, 
doripenem, and ertapenem. Enterobacteriaceae may be categorized as carbapenem-resistant 
based upon antimicrobial susceptibility test results following interpretative criteria established 
in the U.S. by the Clinical and Laboratory Standards Institute (CLSI). An Enterobacteriaceae 
currently qualifies as carbapenem-resistant with a minimum inhibitory concentration (MIC) of 
≥4 ug/ml for imipenem/meropenem/doripenem, or ≥2 ug/ml for ertapenem [16, 17]. For 




carbapenem (or that has documented possession of a carbapenemase, see Section 1.2.A.1) 
[18]. Importantly, antimicrobial susceptibility testing does not reveal the molecular mechanism 
conferring carbapenem resistance.   
Figure 1.1. Classification of Gram-Negative Bacilli, with Select Genera and Species* 
 
*Excludes Gram-negative bacilli with special growth requirements 
 
1.2.A.1. CRE Sub-Types 
 
CRE are further distinguishable by their carbapenem resistance mechanisms. Carbapenem 
resistance may be achieved through production of a carbapenemase (CP-CRE) or through 




CP-CRE) (Table 1.1).  Carbapenemases are enzymes that hydrolyze carbapenems and are 
encoded by genes frequently carried on mobile genetic elements such as plasmids and 
transposons [19-22]. Multiple types and sub-types of carbapenemases exist, which are 
generally categorized by their molecular hydrolytic sites [23, 24]. Carbapenemases can transfer 
between bacteria, including across species and families. Epidemiologists fear that 
carbapenemase genes may become established in bacterial strains with heightened 
transmissibility and/or pathogenic potential. Due to the mobility of their plasmid-mediated 
resistance mechanisms and propensity for causing outbreaks, the literature generally expresses 
greater concern for CP-CRE [25]. CP-CRE are also associated with poorer clinical outcomes 
compared to non-CP-CRE [26].   
 
Non-CP-CRE arise through mechanisms other than carbapenemase production. These 
mechanisms most commonly include production of extended-spectrum β-lactamases (ESBLs) 
and/or AmpC cephalosporinases (AmpCs), in combination with cell membrane alterations. 
ESBLs are generally plasmid-encoded, and AmpCs generally result from either deregulation or 
induction of a chromosomally-encoded ampC gene or from acquisition of a plasmid-encoded 
AmpC gene (e.g., blaCMY) [23, 27]. ESBLs and AmpCs are sometimes capable of hydrolyzing 
carbapenems at very low levels [28, 29], but in combination with membrane impermeability 
(principally arising from mutated or absent porin channels) or increased drug efflux [30, 31], are 
effective at preventing carbapenems from reaching their binding targets at sufficient 




Table 1.1.  Underlying Molecular Resistance Mechanisms in Carbapenem-Resistant 
Enterobacteriaceae (CRE)* 
 
Carbapenemase-Producing CRE (CP-CRE) 
MOLECULAR RESISTANCE MECHANISM EXAMPLES 
Ambler Class A: Serine Carbapenemases KPC; SME; GES 
Ampler Class B: Metallo-β-Lactamases  NDM; IMP; VIM 
Ambler Class D: Serine Carbapenemases  OXA-23, -24, -48 
Non-Carbapenemase-Producing CRE (non-CP-CRE) 
Ambler Class A: ESBL + porin alterations or 
increased efflux pump activity 
CTX-M-group; SHV-type; TEM-type 
Ambler Class C: AmpC hyper-expression  + porin 
alterations or increased efflux pump activity 
Inducible AmpC β-lactamases 
(Enterobacter spp., Citrobacter spp., 
Serratia marcescens, et cetera.) or E. coli 
possessing chromosomal ampC promoter 
and/or attenuator mutations 
Plasmid-mediated AmpC (Ambler class C) + porin 
alterations or increased efflux pump activity 
CMY; ACT; DHA 
Abbreviations: Klebsiella pneumoniae carbapenemase (KPC); New Delhi metallo-β-lactamase (NDM); Imipenemase 
metallo-β-lactamase (IMP); Verona integron-encoded metallo-β-lactamase (VIM); Oxacillinase metallo-β-lactamase 
(OXA); Extended-spectrum β-lactamase (ESBL); AmpC cephalosporinase (AmpC)  
*Adapted from Goodman KE, Simner PJ, Tamma PD, Milstone AM. Infection control implications of heterogeneous 




1.2.B. Other, Non-CRE Carbapenem-Resistant Organisms (CROs) 
 
Although CRE have received significant attention [9], other non-Enterobacteriaceae bacteria 
commonly found in the GI tract are an emerging reservoir of  carbapenem resistance [35, 36]. 
Of these, the most notable are the glucose non-fermenting Gram-negative bacilli (glucose non-
fermenters). This bacterial family encompasses important healthcare-associated pathogens, 
including Pseudomonas aeruginosa and Acinetobacter baumannii (Figure 1.1). In addition to the 




tract and nares/pharynx [37-39]. Glucose non-fermenters can cause serious clinical infections, 
particularly in patients with underlying comorbidities. The CDC has designated MDR glucose 
non-fermenters, including those which are carbapenem-resistant, as a “serious” public health 
threat [9].  
 
Concurrent with the general increase in carbapenem resistance among glucose non-fermenters 
has been the continued dissemination of carbapenemases among these bacteria. All 
carbapenemase classes have now been detected in Acinetobacter and Pseudomonas species 
[40], with the Ambler class D carbapenemases (e.g, OXA-23) most common in the former and 
the class B carbapenemases (e.g., VIM) most common in the latter [41]. Carbapenemases can 
also migrate between Enterobacteriaceae and glucose non-fermenting bacteria, and 
carbapenemases traditionally observed in CRE (e.g., KPC, NDM) have been detected in glucose 
non-fermenters [42, 43]. Like CP-CRE, carbapenemase-producing glucose non-fermenters have 
caused nosocomial outbreaks with resulting serious clinical infections [44, 45]. Collectively, CP-
CRE and carbapenemase-producing glucose non-fermenters constitute carbapenemase-
producing organisms (CPOs). 
 
1.3. Strategies for Reducing Carbapenem Resistance in Healthcare Settings  
 
Strategies for minimizing carbapenem resistance in healthcare settings are complementary and 




antibiotic stewardship programs, and infection control policies to reduce nosocomial spread 
following resistance emergence or CRO acquisition.  
 
1.3.A. Reduce Carbapenem Use  
 
For a variety of nosocomial pathogens, including CRE and other CROs, antibiotic exposure is a 
risk factor for subsequent colonization or infection [46-50].  The processes underlying this 
association are complex. CROs may endogenously arise in patients receiving antibiotic therapy 
through a variety of mechanisms, including “classical” selective pressure but also through 
ecological effects on the microbiota.   
 
First, CROs may arise in previously-susceptible patient microbiota during antibiotic exposure 
when de novo mutations confer resistance to select antibiotics or antibiotic classes. 
Carbapenemases, which are often encoded on mobile genetic elements such as transposons or 
plasmids, do not primarily arise from de novo mutation in bacterial cells and are not anticipated 
to endogenously arise during antibiotic therapy [41]. In contrast, non-CP-CROs can emerge if a 
patient with an infection receives carbapenem therapy, and the organism mutates to acquire a 
mutation in a membrane protein (i.e., porin), such that carbapenems can no longer cross into 
the bacterial cell [51-54].  Multiple studies and case reports have documented non-CP-CRE 
emergence following prolonged carbapenem treatment [55-59], and a large surveillance study 





Second, carbapenem therapy may exert selective pressure that enriches pre-existing CRE or 
other CROs. This selective pressure may allow CROs to flourish and may account for some of 
the extensively documented association between carbapenem exposure and subsequent 
carbapenem-resistant infection, particularly in endemic settings.  
 
Third, carbapenem exposure may increase the risk of both CRO transmission and acquisition, 
although available data are more robust for CRE. Recent antibiotic exposure prior to CRE 
detection is associated with higher CRE bacterial load in fecal samples [61]. Higher bacterial 
burden may increase the risk of environmental contamination or transmission to others [62]. 
Conversely, antibiotic exposure may increase susceptibility to colonization among CRE-negative 
patients by disrupting the intestinal microbial ecology, leading to a loss of colonization 
resistance. Healthy commensal microbiota provide ecologic niche protection against externally 
encountered pathogens through competitive exclusion and inflammation-mediated 
mechanisms [63, 64]. Any antibiotic, including carbapenems, has the potential to cause gut 
dysbiosis [65].    
 
Achieving reductions in carbapenem use is challenging. Currently, carbapenems are neither 
available orally nor first-line therapy for most infections, and are therefore already used more 
judiciously than many other antibacterial classes. Nevertheless, important opportunities for 
reducing carbapenem administration remain. Although less drug-resistant than CROs, ESBL-




Importantly, because ESBLs can hydrolyze most broad-spectrum β-lactam antibiotics except 
carbapenems, carbapenems are generally the treatment of choice for serious ESBL infections 
[54, 67]. However, clinical microbiology laboratories currently require at least 24 additional 
hours from the time of microbial genus and species identification to confirm ESBL production; 
many other U.S. laboratories, including at the Johns Hopkins Hospital, have abandoned routine 
ESBL confirmatory testing due to resource constraints and because it is no longer required by 
CLSI guidance [16, 68]. Consequently, clinicians must generally select treatment for patients 
with serious Gram-negative infections without knowing whether the infection is ESBL-
producing. These empirical treatment decisions must balance the risk of ineffective therapy 
against the resistance risks posed by overly broad antibiotic treatment. Erring towards caution 
in critically-ill patients and administering carbapenems understandably, but nevertheless 
concerningly, contributes to further carbapenem resistance development.  
 
1.3.B. Reduce CRO Introduction and Transmission 
 
While reducing the emergence of carbapenem resistance is one important element of CRO 
prevention, mitigating the transmissibility of CROs that do emerge or are otherwise introduced 
into healthcare facilities is of equal importance. Due to the significant nosocomial outbreak 
potential and clinical harms posed by CRE, the CDC has published comprehensive guidance for 
controlling CRE in healthcare settings; many of these policies are also relevant to other CROs 
[69]. Recommendations include rigorous hand hygiene and environmental cleaning compliance, 




for all patient contact), and the consideration of staff and/or geographic cohorting of CP-CRE 
cases (e.g., physically separating patients or providing dedicated equipment or healthcare 
workers) [69].  
 
The arguably missing element to this otherwise robust strategy is routine active surveillance for 
CRE or CRO colonization among high-risk populations (e.g., intensive care unit patients), which 
is a cornerstone of HAI prevention for many MDR Gram-positive organisms [70, 71]. Unlike 
infections, which are detected in the routine course of clinical care, identifying asymptomatic 
CRE colonization requires surveillance, generally with rectal or peri-rectal swabs. The CDC 
recommends limited CRE colonization surveillance, including patients with recent international 
hospitalization and contacts of confirmed CP-CRE cases [69]. Compliance with surveillance 
swabbing is often poor and wide-scale screening in U.S. hospitals remain uncommon. 
Unfortunately, recent studies suggest that existing policies and current recommendations may 
miss many CRE colonized patients [72]. Diagnostic challenges, including workflow and cost 
considerations, underlie the current impracticality of universal surveillance for CRE and other 
CROs. Moreover, due to the existing lack of screening, colonization prevalence among inpatient 
populations remains poorly quantified — i.e., the specific data necessary to inform evidence-
based assessments about whether and how to expand screening programs. Better 
understanding the burden of CRO and CPO carriage and who to target for screening will be 





1.4. Diagnostics for CROs and Other MDRGNs 
 
Successful carbapenem resistance prevention strategies, whether targeted at reducing 
antibiotic use or at interrupting transmission, hinge on the ability to rapidly, and cost-
effectively, identify patients harboring CROs and other MDRGNs, as well as to distinguish their 
underlying resistance mechanisms. While diagnostics for CROs have remained relatively 
unchanged, CPO diagnostics are advancing rapidly. Multiple assays for carbapenemase 
detection became clinically available in recent years, and others are in late-stage research 
testing [73, 74]. Each available method, either for CROs more broadly or CPOs more specifically, 
however, has limitations. These diagnostic limitations threaten our ability to effectively 
characterize and respond to evolving CRO and CPO epidemiology.  
 
Well-established methods are available for identifying CRE or other CROs, whether from clinical 
specimens or surveillance swabs. Because CROs, including CRE, are defined in reference to their 
antibiotic resistance profile, however, identifying them requires organism culture and 
subsequent antibiotic susceptibility testing (AST). In the case of surveillance swabs, for 
example, from the time of laboratory receipt, culturing (e.g., direct plating or broth enrichment) 
requires ~24 hours, followed by an additional 24 or more hours to obtain AST results [75, 76]. 
This process is relatively inexpensive but has a long turnaround time, depending on the method 
may impose significant workflow and personnel constraints, and may exhibit reduced sensitivity 
in swabs with low organism burden. After two days, it also remains unknown whether 





Various phenotypic tests are available to identify carbapenemases, but these tests have 
historically performed poorly or had other important limitations. Newer assays for identifying 
carbapenemase production have achieved high sensitivity and specificity, and the CDC now 
encourages laboratories with sufficient institutional capacity to test CRE isolates for 
carbapenemases for epidemiological purposes [69]. For example, the Carba NP, which produces 
a color change in the presence of carbapenemase-induced imipenem hydrolysis, is highly 
accurate in CRE (with the exception of identifying OXA-48-like carbapenemases) and has a fast 
turnaround time of approximately two hours [75, 77]. However, the Carba NP test uses 
reagents with short shelf-lives and may be challenging to incorporate into routine laboratory 
workflows. Commercial versions of this and similar tests resolve this problem but, at a cost of 
$2-10 per test, may be prohibitively expensive for wide-scale screening [73]. The modified 
carbapenem inactivation method (mCIM), another phenotypic assay for carbapenemase 
production, is accurate, relatively simple to implement, and only costs ~$1 per test. However, it 
requires overnight incubation, thereby lengthening processing time [78, 79].  
 
Importantly, each of the phenotypic tests discussed above require cultured isolates. In theory, 
one could perform these tests following organism identification without waiting for AST results 
(e.g., ~12-24 hours after specimen collection), but given the presumed low CPO prevalence in 
U.S. facilities, this approach would be high-resource, low-yield, especially for screening. On the 




phenotypic testing produces an approximately 2.5-3 day turnaround time. Particularly for 
shorter ICU admissions, patients could be discharged before isolate processing is complete. 
Alternative methods (e.g., carbapenemase chromogenic media) can shorten this window to 
approximately 24 hours from laboratory receipt, but they are labor-intensive and with poorer 
sensitivity/specificity profiles they would likely require subsequent confirmatory testing [75, 
77]. 
 
Molecular methods identify carbapenemase genes through nucleic acid amplification and can 
be performed directly from specimens or swabs without the need to culture. These methods 
can produce results within a few hours from swab collection, but at potentially prohibitive 
expense. DNA isolation and extraction can also be challenging for some assays (e.g., Check-
Points), and although faster methods such as the CARBA-R are available, they currently cost 
~$50 per test and run fewer samples per batch [80, 81]. Moreover, because amplification 
(without prior organism enrichment) can fail if bioburden is insufficient, real-time molecular 
methods for surveillance screening may perform better with rectal rather than perirectal swabs 
[82]. This shift would entail attendant practical challenges and need for floor staff re-education.  
 
Of note, although some of the preceding limitations will likely lessen as technology advances, 
others are likely to persist. As experience with older MDRGNs, including ESBLs, illustrates, most 
confirmatory testing still requires an additional 24 hours after AST results are known. 




despite the availability of various molecular assays, they are not routinely utilized. As 
healthcare facilities consider whether and how to implement CRO screening programs, they 
have and will continue to grapple with these challenges.  
 
1.5. Statistical and Machine Learning Approaches for Circumventing MDRGN Diagnostic 
Limitations 
 
Statistical models for identifying CRO, CRE and other MDRGNs can help to address existing 
diagnostic limitations. Logistic regression-derived risk prediction scores are common in the 
clinical infectious disease and healthcare epidemiology literature. They have been used, for 
example, to predict risk of drug-resistant pneumonia in patients presenting to emergency 
departments [83] and risk of VRE bloodstream infection following hematopoietic stem cell 
transplantation [84]. These models are attractive because they are relatively simply to develop 
and allow individual users to alter score cut-points in order to prioritize sensitivity or specificity 
for a given application. However, risk scores may also be cumbersome to implement manually 
depending upon the number of included variables and complexity of end-user calculations. Of 
note, significance-based variable selection procedures, as are commonly used to build 
multivariable logistic regression models and risk scores, may perform poorly for prediction [85]. 
Alternative methods more suited to prediction goals (e.g., lasso regression [86]) are available. 
 
Other approaches for developing clinical prediction tools include tree-based machine learning 




example, is an approach rarely utilized in the clinical antibiotic resistance literature that may be 
helpful as a practical predictive modeling tool in these circumstances [87]. Decision trees use a 
series of continuous and/or categorical input variables to predict an outcome. Classification 
trees predict categorical outcomes, and regression trees predict continuous outcomes. These 
trees, which rely on branching logic, are simple to interpret and generally do not require 
calculations [87-89]. Decision trees are prone to overfitting, however, potentially limiting their 
generalizability without appropriate methodological corrections and internal or external 
validation. Random forests analysis, an ensemble approach that produces many bootstrapped 
decision trees, addresses many of these challenges although it does not produce a single, easily 
interpretable tree [90, 91]. In hospitalized settings, random forests have commonly been used 
in emergency departments to build electronic triage models for risk-stratifying patients [92, 93]. 
 
1.6. Summary of Current Challenges and Gaps in Knowledge 
 
Current prevention strategies for CROs and CPOs are hampered by a lack of rapid and cost-
effective diagnostics to identify these and other MDRGN organisms. Statistical approaches can 
help fill knowledge gaps that are critical to reducing CRO acquisition and spread in U.S. 
healthcare facilities.  
 
First, available data on the prevalence of carbapenemase-producing and non-carbapenemase-




susceptibility testing (AST) cannot distinguish carbapenem resistance mechanisms, and current 
CLSI guidance does not recommend routine confirmation of carbapenemase production among 
CRO isolates. Many U.S. diagnostic laboratories therefore do not distinguish CROs from CPOs 
for therapeutic decision-making, rendering data from clinical specimens largely uninformative 
[68, 94, 95]. Data on CRO and CPO colonization prevalence are even more limited, because 
unlike clinical infections, colonization detection requires active surveillance. With the exception 
of specific targeted screening (e.g., patients recently hospitalized internationally), most facilities 
do not perform routine CRO or CPO active surveillance due to existing diagnostic limitations. 
The net result of these challenges are missed opportunities for intervening to reduce CRO 
introduction and healthcare-associated transmission. Better understanding the burden of CRO 
and CPO carriage, and risk factors and predictors for colonization (which may differ from clinical 
infection), may improve algorithms for identifying and screening patients at highest carriage 
risk. 
  
Second, diagnostic challenges persist even for older, less resistant MDRGNs (e.g. ESBLs), which 
contributes to ongoing CRO emergence by facilitating unnecessary carbapenem use. 
Carbapenems remain the treatment of choice for serious ESBL infections, but specimen 
collection-to-ESBL-confirmation still requires approximately three days; many other 
laboratories have abandoned ESBL confirmatory testing entirely. Additionally, although 
molecular methods are faster, commonly used Gram-negative molecular panels do not include, 




must select empirical antibiotic treatment for patients with serious Gram-negative infections 
without knowing whether the causative organism is ESBL-producing, while balancing the risk of 
ineffective therapy against overly broad antibiotic treatment. The ability to discriminate rapidly 
between ESBL-positive and ESBL-negative infections at the point of treatment initiation could 
reduce inappropriate carbapenem administration.    
 
Third, prediction models can help to address these diagnostic challenges by complementing 
microbiological methods. Recognizing that wide-scale CRO screening remains impractical, these 
models can help to identify who to target for screening in order to allocate resources 
efficiently. Clinically, they can also help to guide who can be more conservatively treated with 
carbapenem-sparing antibiotic regimens in the absence of, or while awaiting, microbiological 
confirmation. Yet, these approaches remain under, or at a minimum non-optimally, utilized in 
the clinical infectious disease and healthcare epidemiology literature. Older, more traditional 
methods (e.g., logistic regression-derived risk scores) are common, with desirable attributes. 
However, they frequently rely on significance-based variable selection procedures, which may 
perform poorly for prediction. Newer methods and machine learning-based approaches, e.g., 
decision trees, have practical utility and avoid significance-based, “risk factor” variable selection 
pitfalls. But, despite these benefits, they remain uncommon. Increasing familiarity with these 
methods, as well as refining distinctions between causal inference and prediction, may improve 





1.7. Specific Aims 
 
To address these challenges and knowledge gaps, we aim to:  
1. Estimate the prevalence of and risk factors for, and develop predictive models of, 
colonization with carbapenem-resistant organisms (CROs) and carbapenemase-
producing organisms (CPOs) at hospital unit admission.  This study will utilize a 
prospective cohort of approximately 3,000 patients admitted to the medical intensive 
care unit (MICU) and comprehensive transplant unit (CTU) at The Johns Hopkins 
Hospital (JHH). Patients will have peri-rectal swabs screened for CROs and CPOs at unit 
admission. Comprehensive data on pre-admission exposures will be collected through 
automated extraction from electronic medical records (EMRs). We will develop 
predictive models for colonization through classification and regression tree (CART) 
analysis, a machine learning methodology that yields a user-friendly decision tree 
algorithm, in order to identify patients at high risk of CRO carriage (composite and 
stratified by bacterial class and carbapenemase status). Alternative approaches (e.g., 
random forests analysis) will also be investigated as necessary. 
 
2. Develop a user-friendly clinical decision tree to predict infection with an extended-
spectrum β-lactamase (ESBL)–producing organism, in order to reduce unnecessary 
carbapenem administration. This study includes patients ≥18 years of age with 




2015 at JHH. The retrospective cohort comprises a total of 1288 bacteremic patients, of 
whom 194 (15%) are infected with ESBL-producers (all study isolates underwent ESBL 
confirmatory testing). Pre-infection demographic and clinical data will be collected 
through manual chart review. Recursive partitioning will be used to generate a practical, 
user-friendly decision tree to determine the likelihood that a bacteremic patient is 
infected with an ESBL-producer.  
 
 
3. Methodologically compare decision trees versus risk scores for predicting drug-
resistant colonization or infection. This case study will use the same cohort as Aim 2 in 
order to derive a clinical risk score to predict the likelihood that a bacteremic patient is 
infected with an ESBL-producer. Risk score and decision tree performance will be 
compared, and we will review their practical and methodological attributes. By 
comparing these methods through the lens of a real example, we aim to offer highly 
accessible, general guiding principles for when clinicians or hospital epidemiologists 
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Background. Carbapenem-resistant organisms (CROs), and the subset of carbapenemase-
producing organisms (CPOs), pose urgent challenges to patient care in United States facilities. 
Data on inpatient colonization prevalence are limited. Admission screening for carriage remains 
impractical for many acute care settings. Our objective was to measure the prevalence of, and 
risk factors for, CRO and CPO perirectal colonization at hospital unit admission, and to develop 
predictive models for organism carriage to inform targeted screening programs.   
 
Methods. We performed a prospective cohort study of all patients admitted to the medical 
intensive care unit or comprehensive transplant unit at The Johns Hopkins Hospital between 
July 1, 2016 and July 1, 2017. Using an existing vancomycin-resistant Enterococcus surveillance 
program, admission perirectal swabs were screened for CROs and CPOs. All CPOs were also 
molecularly analyzed. Pre-admission exposure data were collected through automated 
extraction from electronic medical records. We analyzed colonization risk factors with logistic 
regression and developed predictive models with machine learning decision tree 
methodologies. 
 
Results. The study included 3,327 unit visits, with 2,878 (87%) admission swabs available for 




CPOs, respectively. There was high organism and carbapenemase gene diversity among CPO 
isolates. Many clinical characteristics were associated with both CRO and CPO carriage, but 
resulting models did not highly predict colonization. High-risk sub-groups included patients with 
recent CRO-positive cultures who use proton-pump inhibitors. 
 
Conclusions. In this high-risk inpatient population, CRO carriage was infrequent but higher than 
previously published estimates. Colonization was characterized by significant microbiological 






Carbapenem-resistant organisms (CROs) are often resistant to nearly all routinely used 
antibiotics with Gram-negative coverage, and resulting infections are associated with high 
morbidity and mortality [1-6]. Historically, carbapenem-resistant Enterobacteriaceae (CRE) have 
received significant attention [7], but non-Enterobacteriaceae organisms, most notably the 
glucose non-fermenters (e.g., Acinetobacter baumannii, Pseudomonas aeruginosa), are an 
additional and increasingly recognized reservoir of carbapenem resistance genes [8, 9]. Of 
particular concern among CROs are the subset of carbapenamase-producing organisms (CPOs), 
for which carbapenem resistance is generally plasmid-mediated and can transfer between 
organisms, including among different bacterial species and families. CPOs have been implicated 
in high-profile nosocomial outbreaks [10] and, at least among CRE, may be associated with 
poorer clinical outcomes [11].  
 
CRO colonization is an important risk factor for subsequent infection. Admission screening for 
CRO and/or CPO carriage enables rapid isolation of colonized patients and may provide an 
opportunity for individualized care, such as targeted empiric antibiotic therapy or fecal 
transplantation [12-15]. The Centers for Disease Control and Prevention (CDC) recommends 
CRE colonization screening in limited instances [16], but most U.S. hospitals do not perform 
routine CRE or CRO screening. Given limited data on inpatient colonization prevalence in non-
outbreak periods and current limitations of CRO and CPO diagnostics (e.g., cost, turn-around 




data suggests that existing targeted screening policies may miss many colonized patients [17]. 
Better understanding the burden of CRO and CPO carriage, and risk factors and predictors for 
colonization (which may differ from clinical infection), may improve algorithms for identifying 
and screening patients at highest carriage risk. Our objective was to measure the prevalence of, 
and risk factors for, CRO and CPO perirectal colonization at hospital unit admission, and to 
develop predictive models for organism carriage to inform targeted screening programs.   
 
METHODS 
Study Setting and Population  
This study included patients aged ≥ 16 years admitted to the Johns Hopkins Hospital (JHH) 
medical intensive care unit (MICU) or solid organ transplant unit (Transplant Unit), from July 1, 
2016 – July 1, 2017. The MICU provides intensive care for patients with complex and multi-
system medical illnesses, and the Transplant Unit provides intensive and intermediate care for 
adult abdominal organ and reconstructive transplant recipients, as well management of pre-
transplant patients and patients with transplantation medical complications. Both units have a 
longstanding vancomycin-resistant Enterococcus (VRE) surveillance program and collect patient 
peri-rectal Eswabs (Copan) at unit admission (defined as ≤ 2 calendar days from unit entry) and 
weekly thereafter. This study was approved by the Johns Hopkins University School of Medicine 
Institutional Review Board, with a waiver of consent. 
 




Residual Amies media from Eswab collection vials was stored at 4˚C and, within 4 days of swab 
collection, directly plated onto MacConkey agar with ertapenem and meropenem disks [18]. 
Colonies growing within 27 mm of ertapenem and 32 mm of meropenem were identified by 
matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (MALDI-TOF; 
Bruker Daltonics), and carbapenem antimicrobial susceptibility testing (ertapenem, 
meropenem and imipenem) was performed by disk diffusion applying Clinical and Laboratory 
Standards Institute guidelines [19].  
 
Enterobacteriaceae resistant to ertapenem, meropenem, and/or imipenem were categorized as 
CRE. Glucose non-fermenting (NF) Gram-negative bacilli resistant to meropenem and/or 
imipenem were categorized as NFCROs, with the exception of: 1) Stenotrophomonas 
maltophilia, which was excluded due to intrinsic carbapenem resistance, and 2) Aeromonas 
spp., a non-Enterobacteriaceae glucose fermenter, was included for lack of an alternative 
category. CRE and NFCRO isolates were tested for carbapenemase production by the modified 
carbapenem inactivation method (mCIM) [20]. CRE and NFCROs positive for carbapenemase 
production by the mCIM test were defined as CP-CREs and CP-NFCROs, respectively 
(collectively, carbapenemase-producing organisms or “CPOs”). mCIM-negative isolates were 
defined as non-CP-CRE and non-CP-NFCROs (Figure 2.1). CPOs underwent molecular 
carbapenemase genotype testing by the Check-MDR CT103XL assay (Check-Points). All study 




collection, and results were not entered in the medical record, so neither infection control staff 
nor direct care providers knew patients’ colonization status. 
 
Clinical Data Collection  
Patient data were collected retrospectively through automated extraction from JHH electronic 
medical record (EMR), infection control, and administrative databases. EMR data were available 
for inpatient and outpatient encounters across the Johns Hopkins Healthcare system, which 
includes seven hospitals across Maryland and the District of Columbia. Briefly, an experienced 
data user (E.Y.K.) extracted all encounter-level information from a relational database that 
underlies the JHH EMR (Epic). Data relating to demographics, procedures and medication 
administration, laboratory results, and clinical diagnoses were extracted with the same 
structured query language for every patient. Infection control variables (e.g., contact 
precautions status, National Healthcare Safety Network (NHSN)-reportable indwelling 
hardware) were extracted by an experienced data user (A.G.) from Healthcare Epidemiology 
and Infection Control (HEIC) operational databases. 
 
Patient data was based on the day of, or days/weeks prior to, unit admission, and included the 
following: (a) demographic data; (b) hospitalization encounter-level data (e.g., admission type, 
pre-admission location); (c) pre-existing medical conditions and co-morbidities; (d) multidrug-
resistant organism (MDRO) colonization or infection in the prior six months, and contact 




hospitalization in the prior six months; (f) discharge to a post-acute care facility (long-term 
acute care hospital, skilled nursing or rehabilitation facility) in the prior six months; (g) 
indwelling hardware in the prior three months; (h) days and total defined daily dose (DDD)-
adjusted doses [21] of immunosuppressive therapy, proton-pump inhibitors (PPIs), or histamine 
H2-receptor antagonists (H2-blockers) in the prior three months; (i) days and total DDD-
adjusted doses of Gram-negative active antibiotic therapy in the prior three months; (j) invasive 
abdominal procedures or surgeries in the prior three months; and (k) recent international 
exposure, including hospitalization in another country in the prior six months and/or foreign 
travel in the prior 21 days, both assessed by standard nursing intake questionnaire at 
admission. Consistent with CDC guidance [22], Johns Hopkins Healthcare system policy refers 
patients with recent international hospitalization (<6 mos.) for CRE peri-rectal colonization 
surveillance screening at admission. We also calculated a 30-category, unweighted Elixhauser 
Comorbidity Index score (including both primary diagnoses and comorbidities) from the EMR 
[23]. 
 
Statistical Methods   
Data Analysis and Logistic Regression. Descriptive statistics for patient variables were 
calculated using mean (standard deviation [SD]), median (range or interquartile range (IQR)), or 
frequency count (percentage), as appropriate. The relationship between each study covariate 
and the study outcomes was evaluated using univariable logistic regression with general 




unit admissions. Results were summarized by odds ratios (ORs) and corresponding 95% 
confidence intervals (CIs). All tests were 2-tailed, and P values ≤ 0.05 were used for statistical 
significance testing in primary analyses and ≤ 0.025 in sensitivity analyses in order to adjust for 
multiple outcomes (CRO and CPO colonization). Due to the large number of collected variables 
and lack of strong a priori causal hypotheses, we did not perform multivariable logistic 
regression. Descriptive and logistic regression analyses were performed in Stata, version 13.0 
(StataCorp, College Station, TX).  
 
Machine Learning-Derived Predictive Models. We developed predictive models for the 
outcomes of CRO, CRE, and CPO colonization at unit admission that evaluated all available 
collected variables. We built decision trees applying the classification and regression tree 
(CART) algorithm [24] using the rpart (Recursive Partitioning and Regression Trees) package, 
version 4.1–13. To fit our trees, we employed the Gini impurity criterion for splitting rules [25]. 
We also performed random forests analyses to fit 1,000 bootstrapped classification trees, using 
the randomForest package (version 4.6-14). In sensitivity analyses, we tuned model parameters 
for both CART decision trees and random forests to incorporate CRO and CPO outcome prior 
probabilities of 0.50 and 0.10, respectively, in order to address the large imbalances (i.e., rare 
outcomes) in our data and increase model sensitivity. All machine learning predictive models 





Predictive Model Validation. We internally validated the performance of our CART decision 
trees using leave-one-out cross-validation [25]. We evaluated the discrimination of all models, 
both original and cross-validated, through the generation of receiver operating characteristic 
(ROC) curves and calculation of C-statistics (i.e., area under the curve) in R.  
 
RESULTS 
Study Population  
There were 3,327 unit admissions during the study period: 1,796 (54%) in the MICU and 1,531 
(46%) in the Transplant Unit. Of these encounters, 2,878 (87%), representing 2,165 unique 
patients, had stored perirectal admission screening swabs that were processed for CROs (Figure 
2.2).  
 
Patient characteristics are presented in Table 2.1. Evaluating the cohort of swabbed patients 
(n=2878), patients had a mean age of 55 (SD, 15.4) years and 54.0% were male. Twenty-nine 
(1.0%) had documented foreign permanent residence. The majority of hospitalizations were 
emergency/urgent (91.9%), with direct or rapid transfer to the one of the two study units 
(median time-to-unit admission from hospital admission: 0 days, IQR: 0 – 1 days). The median 
unweighted Elixhauser Comorbidity Index score was 4 (IQR, 2-7). The most common principal 
diagnoses or co-morbidities were deficiency anemia (41.8%), renal failure (40.4%), and/or liver 





In the six months preceding unit admission, 54% of patients were hospitalized and 17.5% had a 
prior ICU stay. A combined 173 (6.0%) patients had documented discharge to a long-term acute 
care hospital (1.2%) and/or skilled nursing or rehabilitation facility (5.3%), and 2.6% of patients 
were directly admitted to the hospital from a long-term care facility during the current study 
encounter (excludes long-term acute care hospitals). Thirty patients (1.0%) had documented 
overnight hospitalization in a foreign country. Seventy-four (2.6%) of patient encounters had a 
prior CRO-positive clinical or surveillance culture: 11 CREs and 63 NFCROs. One hundred-and-
seven patients (3.7%) had a prior extended-spectrum β-lactamase (ESBL)-producing or 
ceftriaxone-resistant Enterobacteriaceae culture.  
 
In the three months preceding unit admission, 330 patients (11.5%) had an endoscopic 
procedure: 93 patients (3.2%) had lower endoscopies and 302 (10.5%) had upper endoscopies 
(sum >330 due to co-receipt of both procedures). Three hundred-and-three patients (10.6%) 
had abdominal, colorectal, or urologic surgery. Six hundred-and-seven (21.1%) of patients 
received antibiotics with Gram-negative coverage; 128 (4.5%) received carbapenems. Six 
hundred-and-eleven (21.2%) patients received PPIs or H-2 blockers. 
 
At or on the day preceding unit admission, overall 887 (30.8%) of patients had indwelling 
hardware due to: urinary catheters (21.9%), central lines (13.6%), mechanical ventilation 




systems (0.3%), and/or ostomy (0.03%). Three hundred-and-fifteen (10.9%) of patients were 
positive for VRE on their unit admission surveillance swabs, i.e., on the same swab that was 
processed for CROs. 
 
CRO and CPO Colonization Admission Prevalence 
Overall, 217 of 2,878 admission swabs (7.5%; 95% CI: 6.6 – 8.5%), from 192 unique patients, 
tested positive for one or more CROs (Figure 2.2). The CRO prevalence was higher among MICU 
admissions than among Transplant Unit admissions (9.4% vs. 5.1%, p <0.001). Of the 217 CRO-
positive swabs, 36 (16.7%) were positive for carbapenemase production, from 32 unique 
patients, yielding a CPO colonization admission prevalence of 1.3% (95% CI: 0.9 – 1.7%). The 
prevalence of CPOs was similar in both units (1.3% in the MICU vs. 1.1% in the Transplant Unit, 
p=0.64).  
 
Colonization Admission Prevalence by Bacterial Class: CRE versus NFCROs 
Of the 217 CRO-positive admission swabs, 121 swabs (56%) possessed one or more CREs. These 
121 CRE-positive swabs, from 113 unique patients, comprised 97 non-CP-CRE swabs (from 91 
unique patients) and 24 CP-CRE swabs (from 22 unique patients). The overall prevalence of CRE 
and CP-CRE perirectal colonization at admission was 4.2% (95% CI: 3.5 – 5.0%) and 0.8% (95% 
CI: 0.5 – 1.2%), respectively. Approximately 20% of CRE were carbapenemase-producers. The 




Klebsiella pneumoniae (50%), followed by Enterobacter cloacae (27%), Citrobacter amalonaticus 
(11%), Escherichia coli (8%), and Citrobacter freundii (4%).  
 
One hundred and seven admission swabs, from 92 unique patients, were positive for one or 
more NFCROs, yielding a NFCRO perirectal colonization admission prevalence of 3.7% (95% CI: 
3.0 – 4.4%). Ninety-five of the 107 swabs (88.8%) were non-CP-NFCROs, from 83 unique 
patients, and 12 (11.2%) were CP-NFCROs, from 10 unique patients. Overall, the admission 
prevalence of carbapenemase-producing NFCRO colonization was 0.4% (95% CI: 0.2 – 0.7%), 
relative to a 0.8% point prevalence of CP-CRE colonization. Of the 12 carbapenemase-producing 
NFCROs (no swabs were co-colonized with multiple CP-NFCROs), the majority were 
Acinetobacter baumannii (58%), followed by Aeromonas spp. (17%), and one organism (8%) 
each of: Acinetobacter radioresistens, Achromobacter xylosoxidans, and Pseudomonas 
aeruginosa.  
 
Eleven admission swabs (0.4%), all from unique patients, were co-colonized with both CRE(s) 
and NFCRO(s). Most Enterobacteriaceae in these swabs were K. pneumoniae or E. coli, and the 
majority of the non-fermenters were P. aeruginosa. Three of 11 swabs possessed a CPO, but no 
admission swabs possessed CP-CRE and CP-NFCRO co-colonization. 
 




Thirty-two of 36 CPO-positive swabs, as defined by a positive mCIM test, underwent molecular 
Checkpoints processing. Twenty-three of the 33 (70%) mCIM-positive organisms were 
confirmed to have carbapemenase genes by the Checkpoints assay (one processed swab was 
co-colonized with two CP-CREs). The distribution of organisms and carbapenemase results are 
presented in Table 2.2.  
 
Among CP-CREs, the identified carbapenemases in order of frequency were: blaKPC (67%), 
blaNDM + OXA-48 (17%), blaNDM (11%), and blaOXA-48 (5%). Among the CP-NFCROs, blaOXA-23 and 
blaOXA-24 were the most common carbapenemases (40% each), followed by blaVIM (20%). Only 
two patients with molecularly-confirmed carbapenemases, a blaKPC-producing K. pneumoniae 
and blaOXA-48-producing K. pneumoniae, reported recent foreign travel; none reported recent 
international hospitalization. Of the three patients with blaNDM + OXA-48-producing CRE, one was 
directly transferred from a rehabilitation facility, had a recent endoscopy, and was already 
flagged for CRE in the infection control system. The two remaining patients lacked these and 
other traditional high-risk exposures, but both were immunosuppressed at admission. 
 
Risk Factors for CRO and CPO Colonization at Unit Admission 
In univariable logistic regression analysis accounting for repeat-patient admissions, a large 
proportion of variables were significantly associated with CRO colonization at an α level of .05 
(Table 2.1). These variables were broadly classifiable into the following categories: MDRO 




hardware, and medications (e.g., antibiotics, PPIs or H2-blockers). The most strongly associated 
variables included recent or at-admission presence of ostomy hardware (OR 23.07, 95% CI: 7.06 
– 75.40); recent history of a CRO (OR 12.13, 95% CI: 7.36 – 19.97), CRE (OR 17.72, 95% CI: 4.74 – 
66.24), NFCRO (OR 10.21, 95% CI: 6.03 – 17.28), or ESBL-producing and/or ceftriaxone-resistant 
Enterobacteriaceae culture (OR 5.40, 95% CI: 3.18 – 9.14); recent carbapenem (OR 4.32, 95% CI: 
2.72 – 6.88) or PPI/H2-blocker use (OR 2.16, 95% CI: 1.56 – 2.99); and admit from a skilled 
nursing or rehabilitation facility, relative to a community or Emergency Department admission 
(OR 3.53, 95% CI: 1.84 – 6.77), or recent discharge to a long-term care facility (long-term acute 
care hospital, skilled nursing or rehabilitation facility) (OR 3.04, 95% CI: 1.90 - 4.87).  
 
Restricting to the subset of CPOs, each of the preceding variables remained significantly 
associated with CPO colonization, with the exception of admission from a skilled nursing or 
rehabilitation facility due to model non-convergence/non-estimability (Table 2.1). In addition, 
some variables that were not significantly associated with CRO colonization were significant for 
CPO colonization. These included recent colorectal surgery (OR 26.70, 95% CI: 2.75 – 259.24) 
and recent foreign travel by the patient or a partner (OR 10.80, 95% CI: 2.52 – 46.30).  
 
Both CRO and CPO colonized patients were significantly more likely to test positive for VRE 
colonization at unit admission, i.e., on the same admission swab that was processed for CROs 
(respective ORs: 2.62, 95% CI: 1.85 – 3.73; and 3.39, 95% CI: 1.63 – 7.07). These VRE colonized 




outcomes, respectively. In the two study units, patients who test VRE-positive are placed on 
contact precautions, although not until VRE results become available approximately two days 
after swabbing. However, thirty-five of the 51 CRO-VRE co-colonized patients were already on 
contact precautions for other indications (including prior VRE-positive cultures), before VRE 
results became available. Similarly, 8 of 12 CPO-VRE co-colonized patients were on pre-existing 
contact precautions at unit admission. 
 
Predictive Models of Colonization at Unit Admission  
We evaluated all collected study variables, including permutations (e.g., longer or shorter 
lookback periods, composite and individual variable categories), for inclusion in machine 
learning models in order to optimize predictive potential. Unlike logistic regression, the CART 
and random forests approaches used in these analyses can accommodate high predictor-to-
outcome ratios (i.e., high-dimensional data), variable collinearities, and simple and higher-order 
interaction effects without a priori specification [24]. Because institutions may differ in their 
screening objectives and resources, as well as underlying prevalence and organism distribution, 
we derived models for three alternate outcomes: CRO, CPO, and CRE (included in 
supplementary material) colonization.  
 
CART Decision Trees. The final decision tree for predicting CRO colonization at unit admission 
included three study variables (Figure 2.3). The first question in the tree, also called the root 




classification trees, positive or “yes” responses branch to the right. If “yes,” the second 
question queried (2) Did the patient receive 26 or more days (model-derived cut-point) of PPIs 
in the prior three months?  Those patients meeting these criteria were classified as CRO-
positive (Terminal node 4) with an associated 93% probability. In patients with a CRO history 
but lacking this PPI exposure, the tree questioned (3) Has the patient been hospitalized for 51 
or more days in the prior six months? If “yes,” patients were classified as CRO-positive 
(Terminal node 3, 80% probability) and if “no” were classified as CRO-negative (Terminal node 
2, 74% probability).  
 
For those 2804 patients lacking a recent CRO history (question 1), the root node branched left 
and terminated. Patients lacking this history were classified as CRO-negative (Terminal node 1, 
93% probability).  
 
The overall tree possessed a specificity of 99.9% and a sensitivity of 9.8%. The positive and 
negative predictive values were 87.5% and 93.1%, respectively. Incorporating outcome 
probabilities based on terminal node impurities, the C-statistic for the final tree trained on the 
full dataset was 0.57 and unchanged following cross-validation. Thirty-four CRO-colonized 
patients had a prior CRO history, of whom 29 (85%) were already on contact precautions at unit 
admission. Of the five remaining patients who were not on contact precautions, two additional 




patients was colonized with a non-CP-NFCRO and the other was colonized with a VIM-positive 
CP-NFCRO. 
 
The CPO decision tree truncated at a single variable, history of a CRE-positive culture in the 
prior six months. Its specificity was 99.8%, and its sensitivity was 16.7%. In other words, 16.7% 
(6/36) of CPO-colonized patients had a recent CRE culture preceding admission. The CPO tree’s 
discrimination was 0.58 (unchanged following cross-validation). 
 
Random Forests. Random forests (RF) analysis is similar to CART analysis, or other tree-fitting 
algorithms, except that it generates many bootstrapped decision trees [26, 27]. Its output is less 
easily interpretable because it does not produce a singular, final tree, but as an ensemble 
method it generally improves accuracy and reduces model overfitting, i.e., increases 
generalizability. It also estimates the most important variables for predicting a given outcome 
[27-29]. The C-statistic for CRO colonization in RF analysis was 0.65, a 14% increase from the 
single decision tree (C-statistic 0.57). Consistent with the single decision tree’s placement of a 
recent CRO culture in the root node, which is reserved for the most discriminatory variable, RF 
analysis also identified this exposure as the most important for predicting CRO colonization 
status at admission (Figure 2.4). Using the RF variable rankings, we selected the five most 
important, non-nested variables for inclusion in a multivariable logistic regression model 
(nested variables, e.g., prior CRO culture and prior MDRGN culture, would violate logistic 




were: CRO-positive culture in the prior six months, total days of hospitalization in the prior six 
months, Elixhauser severity of illness score, and total DDD-standardized doses of antibiotics 
with Gram-negative coverage and immunosuppressive therapy in the prior three months. The 
resulting model’s C-statistic was 0.62 (Figures 2.4 and 2.5). 
 
In the RF model for CPO colonization, discrimination also rose (C-statistic 0.70) relative to the 
original CART decision tree. Unlike the single decision tree (which placed a recent CRE history at 
its root node), but consistent with the other models, a recent CRO-positive culture was ranked 
as the most important value for predicting CPO colonization (Figure 2.6). The top five, non-
nested variables in order of importance were: CRO-positive culture in the prior six months, 
Elixhauser severity of illness score, total DDD-standardized doses of antibiotics with Gram-
negative activity in the prior three months, time from hospital-to-unit admission (days), and 
total number of days of immunosuppressive therapy in the three months preceding unit 
admission. In logistic regression incorporating these variables, the C-statistic was 0.70 (Figures 
2.4 and 2.6).  
 
Sensitivity Analyses 
To optimize model performance and address possible outcome misclassification, we performed 
three sensitivity analyses: 1) Refitting decision trees with adjusted prior outcome probabilities 
in order to increase sensitivity by imposing a greater “cost” during tree-building for 




unique-patient encounters (n=2165); and 3) Refitting a decision tree and performing random 
forests analysis for predicting CPO colonization, after restricting the CPO outcome to isolates 
with molecularly-confirmed carbapenemases. These results are discussed in the Supplementary 
Material (Supplement).   
 
DISCUSSION 
Identifying CRO- and CPO-colonized patients at hospital unit admission can facilitate timely 
infection control interventions, such as placing colonized patients on contact precautions, in 
order to limit healthcare-associated transmission. The CDC recommends CRE colonization 
screening in limited instances (e.g., patients with recent international hospitalization [16]), but 
most U.S. hospitals do not perform routine colonization screening for CRE or other CROs. 
Evaluating patients admitted to a medical intensive care unit and a solid organ transplant unit, 
we found that 7.5% and 1.3% of patients were perirectally colonized with CROs and CPOs, 
respectively. Among CROs, the distribution of CRE versus carbapenem-resistant glucose non-
fermenters was roughly similar (54% vs. 46%), with a CRE admission prevalence of 4.2% (95% 
CI: 3.5 – 5.0%). This estimate is somewhat higher than the proportion of CRE (3.1%) among 
clinical isolates reported to the National Healthcare Safety Network in 2015 [30], and 
considerably higher than the 0.5% CRE admission prevalence at a Chicago tertiary-care hospital 






CPO colonization reflected substantial organism and carbapenemase diversity. Approximately 
20% of CRE were carbapenemase-producers, and only half of CP-CREs were K. pneumoniae. 
Consistent with other publicly available data, KPC was the most common carbapenemase 
among CP-CRE [30], but 1/3 of CP-CREs encoded other carbapenemases, including co-
possession of NDM + OXA-48. The proportion of carbapenemase-producers among NFCROs was 
lower (11.2%) and included a variety of organisms; only 1 of 12 CP-NFCRO isolates was P. 
aeruginosa (VIM-producing). Of note, three CP-CREs were Citrobacter amalonaticus, a 
traditionally less common healthcare pathogen. These isolates carried different 
carbapenemases (1 NDM, 1 KPC, and 1 Checkpoints-negative), suggesting there were unlikely to 
be part of an undetected cluster. Recent data document carbapenemase dissemination among 
less common Enterobacteriaceae genera [31], and this finding reinforces that any Gram-
negative bacteria of the gut can serve as a reservoir for further spread of carbapenemases.  
 
In univariable analysis, a large number of study variables were significantly associated with both 
CRO and CPO colonization, even when instituting a more conservative, global significance 
threshold of p ≤ 0.025. Most variables’ odds ratio point-estimates also strengthened in CPO 
analysis. All variables reflecting recent MDRO history (MRSA, VRE, CRO, CRE, and ESBL) were 
significantly associated with colonization, with prior CRO or CRE cultures being the strongest. 
These findings comport with the overlap in risk factors (e.g., antibiotic use, exposure to high-
risk healthcare facilities) among drug-resistant organisms [32-34], and in the case of CRO or CRE 




colonization [12-14] and colonization persistence [35]. Other significant variables were 
consistent with published risk factors for CRE/CRO carriage or infection in other populations, 
including but not limited to, antibiotic exposure overall [36-38] or carbapenems specifically [39, 
40]; long-term care facility stay [41, 42]; immunosuppression [36]; endoscopic procedures [38, 
39, 43]; and indwelling hardware [36, 41, 44]. We did not observe strong associations for 
diabetes mellitus, as other studies have identified [45, 46], or for recent international 
hospitalization. In fact, no CPO-colonized patients had documented recent international 
hospitalization, the current CDC-recommended exposure for targeted CRE screening [22]. 
However, recent foreign travel was strongly associated with CPO colonization.  
 
Despite the large number of significant variables, our models did not highly predict colonization 
at unit admission. A decision tree to predict CRO colonization possessed an overall C-statistic of 
0.57, driven largely by very low (9.8%) sensitivity. Even though its global performance was sub-
optimal, however, the decision tree did reveal high-risk sub-groups. Patients with a recent CRO-
positive culture (≤ 6 mos.) who had also been on PPIs for 26 or more days of the last three 
months were 93% likely to be CRO-colonized (13 of 14 patients). Recent studies have identified 
PPI use as a significant risk factor for admission carriage of other MDRGNs (e.g., ESBLs) [47]. 
Among patients with a recent CRO history but without this duration of PPI usage, those who 
had been hospitalized for 51 or more days in the prior six months were 80% likely to be 
colonized (8 of 10 patients). Using these criteria for targeted surveillance would capture 21 




As a practical note, we recognize that algorithm-derived cut-points of 26 and 51 days may be 
difficult to capture without EMR-automated extraction. We encourage future evaluation after 
converting these variables to more user-friendly metrics (e.g., “4 weeks” versus 26 days).  
 
Random forests (RF) models were less readily interpretable than the single decision trees, but 
they improved classifier discrimination, particularly for CPO colonization (RF C-statistic for CPO 
colonization, 0.70). An appealing feature of RF analysis is that it ranks variables by their 
predictive strength, and these variables may be subsequently evaluated in other, more user-
friendly models (e.g., logistic regression). We evaluated the top five variables in a multivariable 
logistic regression model for CPO colonization, with similar model performance (C-statistic, 
0.70). Of note, some variables clustered closely in terms of their predictive power, as reflected 
in the variable importance plots. This information may guide practical variable selection 
decisions when designing targeted screening or other prediction tools — e.g., if variables’ 
predictive strength is roughly equivalent, use the exposure that is simplest to ascertain.  
 
The sub-optimal sensitivity of our predictive models, in particular our primary decision trees, 
was likely driven by a combination of factors. These lessons may be informative to future 
research. First, risk factors measure relative effects, and strong risk factors can account for few 
absolute numbers of cases. For example, one of the strongest risk factors in univariable 
regression and the most discriminatory predictor in most of our decision trees – a recent CRO 




factors and predictors is further underscored by the fact that of the five most predictive 
variables from our best-performing RF model, most were not independently significant in the 
corresponding multivariable logistic regression model. These variables would be missed by 
traditional stepwise variable selection procedures that rely upon significance testing [48]. 
Second, high predictor heterogeneity, with few dominant exposures, can compromise 
predictive accuracy. Because organism identity would not inform differential infection control 
interventions, we did not restrict to specific species (e.g., K. pneumoniae, P. aeruginosa), as is 
common in other published analyses [30, 49]. Moreover, many existing models predict clinical 
infection, not colonization (e.g., [49]). Infection models may differentially capture predictors of 
colonization-to-infection progression (a potentially more predictable, homogenous process) 
rather than risk factors for acquisition. In addition, given the long duration of CRE carriage 
documented in the literature, acquisition risk factors may predate the time-scales captured in 
the EMR. Third, although we collected extensive information on pre-admission healthcare-
associated exposures, the poor model sensitivity among patients lacking a recent CRO history 
may suggest that important predictors were missing for this population. Indeed, although risk 
factors for CRE and other CROs in U.S. patients have traditionally focused on the healthcare 
setting, increasing reports describe the community (e.g., domestic porcine farms, retail 
seafood) as a carbapenem resistance reservoir [50, 51]. These challenges are likely to intensify 






Notwithstanding these challenges, our results offer some actionable conclusions. Across all 
models evaluated, recent CRO or CRE culture was consistently the strongest predictor of 
colonization at admission. Many infection control programs already capture and flag these 
cultures, suggesting that existing policies — however imperfect — may be performing 
equivalently to a targeted screening program. We note, however, that we manually coded our 
‘CRO’ culture definition to synchronize with our CRO study outcome; some NFCRO cultures 
would not qualify as MDRGNs (e.g., resistant to 4/5 antibiotic classes evaluated), as customarily 
defined. Moreover, 24% and 33% of CRO- and CPO-colonized patients, respectively, were co-
colonized with VRE detected during routine admission screening. These patients would be 
placed on contact precautions even without dedicated CRO surveillance. These findings suggest 
that existing screening policies for other organisms may have unrecognized, off-target benefits, 
of arguable relevance to ongoing national conversations about the utility of continued VRE 
rectal surveillance [53].  
 
Our study has several limitations. First, this was a single-center study, and although we 
internally validated our models, our results should be validated in other cohorts. Our results 
may not be generalizable to other, lower-risk hospitalized populations or areas with higher 
endemicity (e.g., New York City). Second, we used culture-based laboratory methods to isolate 
CROs. Culture-based methods can produce false-negative results, particularly for surveillance 
swabs with low bioburden [54, 55]. However, our screening methodology was selected to 




recovery rates were consistent with, or higher, than other published estimates. Third, 
concordance between phenotypic and molecular carbapenemase assays was lower than 
expected. The mCIM demonstrates very high sensitivity and specificity in published data [20], 
but our experience suggests that its specificity may be lower than previously reported, 
particularly for E. cloacae. We repeated mCIM tests on the four mCIM+, Checkpoints-negative 
E. cloacae isolates with identical results, and whole genome sequencing suggested these 
isolates did not encode novel carbapenemases (data unpublished). Nevertheless, in sensitivity 
analyses we restricted the CPO outcome to molecularly-confirmed isolates, with similar 
findings, suggesting that our models were robust to this possible misclassification. Finally, 
despite gathering extensive demographic and clinical information on all study patients, due to 
our restriction to Johns Hopkins Healthcare system data, there was inevitably missing data that 
could lead to exposure misclassification. However, because we would not expect this 
missingness to be differential by colonization status, any associations would likely attenuate 
towards the null; yet, many exposures remained strongly associated with CRO and CPO 
colonization in regression analyses. More importantly, because the prediction models were 
designed to inform practical, real-world screening decisions, their performance under the 
operational constraints of incomplete data is arguably relevant.  
 
Overall, in this high-risk inpatient population CRO and CPO carriage was infrequent but higher 
than previously published estimates. Colonization was characterized by significant organism 




single or few clonal strains. We identified carbapenemases in many organism types, including 
glucose non-fermenters other than A. baumannii and P. aeruginosa and organisms not 
commonly associated with healthcare infections (e.g., C. amalonaticus), providing an important 
reminder that many different GI-colonizing organisms can serve as carbapenemase gene 
reservoirs. Many pre-admission exposures were strongly associated with CRO and CPO 
colonization, consistent with risk factors identified in other published studies, but organism and 
resistance mechanism heterogeneity made prediction challenging. Active surveillance for CROs 
and CPOs is cost and/or resource-intensive, and although were unable to develop high-
performing targeted screening algorithms, ongoing efforts should continue to use available 
EMR and other data to identify ways to limit resource utilization.  
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Figure 2.1. Study Outcome Definitions by Bacterial Class 
 
 
*Glucose-fermenting Aeromonas spp. included in glucose non-fermenting category, as a non-Enterobacteriaceae. 
Abbreviations – Carbapenem-resistant organisms (CROs); Carbapenemase-producing organisms (CPOs); Carbapenem-resistant 
Enterobacteriaceae (CRE); Carbapenemase-producing CRE (CP-CRE); Non-carbapenemase-producing CRE (Non-CP-CRE); Glucose 
non-fermenting carbapenem-resistant organisms (NFCROs); Carbapenemase-producing NFCROs (CP-NFCROs); Non-carbapenemase-




Figure 2.2. Study Flowchart of Carbapenem-Resistant Organism (CRO) and Carbapenemase-














Table 2.1.  Description of Patient Characteristics in a Cohort of Medical Intensive Care Unit 
(MICU) and Comprehensive Transplant Unit (Transplant Unit) Patients, by Carbapenem-
Resistant Organism (CRO) and Carbapenemase-Producing Organism (CPO) Colonization Status 
at Unit Admission 














CRO ; CPO 
 n = 2878 n = 217 n = 36  
Demographics     
Age 55 ± 15.4 1.01 (1.00 – 1.03) 1.01 (0.98 – 1.04) 0.01*; 0.54 
Female sex 1325 (46%) 0.99 (0.74 – 1.34) 0.76 (0.36 – 1.60) 0.97;  0.47 
Race     
   White 1317 (46%) Reference Reference  Reference 
   Black 1272 (44%) NA NA NA 
   Asian 61 (2%) NA NA NA 
   American Indian, Alaska Native or 
Native Hawaiian, or Pacific Islander 
13 (0.5%) NA NA NA 
   Other 215 (7%) NA NA NA 
Foreign Permanent Residence 29 (1%) 2.10 (0.75 – 5.92) 3.77 (0.49 – 
29.01) 
0.16; 0.20 
Encounter-Level Characteristics     
Admission type     
   Emergency/urgent (non-trauma) 2646 (92%) Reference Reference  Reference 
   Trauma 26 (1%) NA NA NA 
   Non-urgent/elective 206 (7%) NA NA NA 
Admission source     
   ER/Community 2353 (82%) Reference Reference  Reference 
   Acute care hospital, direct transfer 434 (15%) 1.63 (1.13 – 2.35) NA 0.01* 
   Long-term care facility (non-acute), 
direct transfer 
74 (3%) 3.53 (1.84 – 6.77) NA <0.001* 
   Other/unknown 17 (0.6%) 0.93 (0.12 – 7.12) NA 0.95 
Elixhauser Comorbidity Score and 
Select Pre-Existing Medical 
Conditions 
    
Elixhauser Score, median (IQR) 4 (2 – 7) 1.02 (0.98 – 1.07) 1.04 (0.95 – 1.12) 0.26; 0.40 
Chronic peptic ulcer disease 81 (3%) 1.47 (0.71 – 3.08) 1.19 (0.23 – 6.07) 0.30; 0.83 
Solid tumor without metastasis 468 (16%) 1.24 (0.85 – 1.82) 1.40 (0.59 – 3.36) 0.27; 0.45 
Metastatic cancer 197 (7%) 1.50 (0.90 – 2.50) 1.13 (0.33 – 3.90) 0.12; 0.84 




Liver disease 852 (30%) 0.78 (0.56 – 1.10) 1.20 (0.57 – 2.50) 0.15; 0.64 
Diabetes 912 (32%) 1.36 (1.00 – 1.85) 1.12 (0.54 – 2.34) 0.05; 0.76 
Iron-deficiency anemia 1203 (42%) 1.22 (0.91 – 1.64) 1.57 (0.75 – 3.28) 0.18; 0.23 
Chronic pulmonary disease 630 (22) 0.99 (0.68 – 1.43) 1.06 (0.45 – 2.51) 0.95; 0.90 




Human Immunodeficiency Virus 
positive 
159 (6%) 0.68 (0.33 – 1.40) 0.48 (0.07 – 3.53) 0.30; 0.48 
Immunosuppressed1 772 (27%) 1.31 (0.94 – 1.83) 1.81 (0.82 – 4.01)  0.11; 0.14 
Indwelling Hardware at Admission 887 (31%) 1.60 (1.19 – 2.16) 2.12 (0.95 – 4.73) 0.002*; 0.07 
Central line 393 (14%) 1.54 (1.05 – 2.25) 2.56 (1.08 – 6.06) 0.03*; 0.03* 
Urologic catheter 631 (22%) 1.20 (0.86 – 1.66) 1.73 (0.77 – 3.88) 0.28; 0.19 
Mechanical ventilation 207 (7%) 1.33 (0.79 – 2.25) 0.32 (0.03 – 4.03) 0.28; 0.38 
Gastrointestinal upper or lower tube 122 (4%) 1.04 (0.50 – 2.18) NA 0.91 
Fecal management device 8 (0.3%) 2.94 (0.43 – 
20.10) 
NA 0.27 
Ostomy 1 (0.03%) NA NA NA 
Indwelling Hardware (< 3 Months) 1148 (40%) 1.74 (1.31 – 2.31) 3.51 (1.56 – 7.94) <0.001*; 
0.003* 
Central line 569 (20%) 1.60 (1.15 – 2.22) 3.66 (1.72 – 7.81) 0.01*; 
0.001* 
Urologic catheter 876 (30%) 1.35 (1.01 – 1.82) 2.32 (1.06 – 5.10) 0.04; 0.04 
Mechanical ventilation 324 (11%) 1.71 (1.13 – 2.60) 2.31 (1.09 – 4.90) 0.012*; 0.03 
Gastrointestinal upper or lower tube 189 (7%) 2.09 (1.28 – 3.40) 1.21 (0.26 – 5.65) 0.003*; 0.81 
Fecal management device 0 (0%) NA NA NA 
Ostomy 13 (0.5%) 23.07 (7.06 – 
75.40) 




On Contact Precautions at Admission 
(Prior to VRE Screening) 
796 (28%) 2.28 (1.68 – 3.09) 3.19 (1.49 – 6.83)  <0.001*; 
0.03 
Admission Swab Positive for VRE 
Colonization 
315 (11%) 2.62 (1.85 – 3.73) 3.39 (1.63 – 7.07) <0.001*; 
0.001* 
Recent Multidrug-resistant Organism 
History (Colonization or Infection <6 
Months) 
    
Vancomycin-resistant Enterococcus 
species. 












(ESBL) or ceftriaxone-resistant 
Enterobacteriaceae 









74 (3%) 12.13 (7.36 – 
19.97) 




     Carbapenem-resistant 
Enterobacteriaceae (CRE) 
11 (0.4%) 17.72 (4.74 – 
66.24) 





non-fermenting bacilli (NFCRO) 
64 (2%) 10.21 (6.03 – 
17.28) 






28 (1%) 9.18 (3.33 – 
25.25) 






41 (1%) 12.86 (6.01 – 
27.54) 




Recent Medication Exposure (< 3 
Months) 
    
Immunosuppressive therapy3 620 (22%) 1.54 (1.09 – 2.19) 2.07 (0.86 – 4.97) 0.02*; 0.10 
Proton-pump inhibitors (PPIs) or H2-
Blockers 
611 (21%) 2.16 (1.56 – 2.99) 3.08 (1.37 – 6.93) <0.001*; 
0.007* 
Recent Antibiotic Exposure (<3 
Months) 
    
Extended-spectrum penicillin therapy 313 (11%) 2.13 (1.42 – 3.19) 3.80 (1.49 – 9.70) <0.001*; 
0.01* 
Third and fourth-generation 
cephalosporin therapy 
379 (13%) 1.33 (0.86 – 2.03) 1.87 (0.72 – 4.85) 0.20; 0.20 
Aztreonam therapy 21 (0.7%) 4.86 (1.78 – 
13.25) 
5.83 (0.92 – 
36.81) 
0.002*; 0.06 




Fluoroquinolone therapy 144 (5%) 2.20 (1.27 – 3.82) 1.69 (0.35 – 8.15) 0.01*; 0.51 
Aminoglycoside therapy 49 (1.7%) 4.91 (2.26 – 
10.64) 




Any antibiotics (combined) 607 (21%) 1.92 (1.39 – 2.64) 2.07 (0.88 – 4.92) <0.001*; 
0.10 
Duration of Time from Hospital 
Admission to Unit Admission (Days), 
median (IQR) 
0 (0 – 1) 1.01 (1.01 – 1.02) 1.01 (1.01 – 1.02) <0.001*; 
<0.001* 
Recent International Exposure      
International Hospitalization (1+ 
nights, < 6 Months) 
30 (1%) 1.72 (0.58 – 5.12) 3.34 (0.46 – 
24.32) 
0.33; 0.23 
International travel, patient or spouse 
(< 21 days) 
18 (0.6%) 2.62 (0.79 – 8.71) 10.80 (2.52 – 
46.30) 
0.12; 0.001* 
Other High-Risk Healthcare 
Exposures (<6 Months) 
    




Intensive care unit 503 (17%) 1.93 (1.38 – 2.69) 2.66 (1.20 – 5.88) <0.001*; 
0.02* 




    Long-term acute care  hospital 34 (1%) 3.70 (1.42 – 9.64) NA 0.01* 
    Skilled nursing or rehabilitation 
facility 




Invasive Procedures (< 3 months)     
Endoscopy 330 (11%) 1.89 (1.27 – 2.83) 1.40 (0.42 – 4.63) 0.002*; 0.59 
    Lower endoscopy 93 (3%) 1.56 (0.67 – 3.65) 1.13 (0.16 – 8.09) 0.31; 0.90 
    Upper endoscopy 302 (11%) 1.64 (1.07 – 2.51) 1.72 (0.50 – 5.95) 0.02*; 0.39 
Bronchoscopy 56 (2%) 0.66 (0.23 – 1.92) NA 0.45 
Surgery 306 (11%) 0.61 (0.35 – 1.08) 1.32 (0.44 – 4.00) 0.09; 0.62 
    Colorectal surgery 6 (0.2%) 2.46 (0.32 – 
18.97) 
26.70 (2.75 – 
259.24) 
0.39; 0.01* 
    Abdominal surgery 282 (10%) 0.59 (0.32 – 1.08) 1.01 (0.29 – 3.49) 0.09; 1.00 
    Urologic surgery 22 (0.7%) 0.44 (0.08 – 2.46) NA 0.35 
 
* Significant at a globally-corrected P-value of ≤ 0.025 (α/2), accounting for two study outcomes (CRO and CPO 
colonization).  
1 Receipt of chemotherapy or immunosuppressive therapy in the prior 3 months, human immunodeficiency virus 
(HIV)-positive, and/or documented CBC immunosuppressive abnormalities within 24 hours preceding unit 
admission (defined as absolute neutrophil counts or total WBC counts less than 500 cells/mm3). 
2 Pan-resistant to 4 of 5 antibiotic classes tested. 
3  Immunosuppressant or non-topical glucocorticoid. 





Table 2.2. Carbapenemase Genes in Carbapenemase-Producing Admission Isolates 
Ambler Class Carbapenemase and Overall 
Percentage (%) Among Identified 
Carbapenemases 
Species No. of Isolates 
(n=38) 
Class A – blaKPC (52%) Klebsiella pneumoniae 8 
 Enterobacter cloacae 2 
 Escherichia coli 1 
 Citrobacter amalonaticus 1 
Class B – blaNDM (9%) 
 
Klebsiella pneumoniae 1 
 Citrobacter amalonaticus 1 





Class D – blaOXA-23 (9%) Acinetobacter baumannii 1 
 Acinetobacter radioresistans 1 
               – blaOXA-24 (9%) Acinetobacter baumannii 2 
               – blaOXA-48 (4%) Klebsiella pneumoniae 1 
Classes B and D – blaNDM + OXA-48 (13%) Klebsiella pneumoniae 3 
Disposition of Remaining Isolates 
Carbapenemase-Gene Negative on Check-
Points Assay 
Enterobacter cloacae (AmpC) 4 
 Acinetobacter baumannii 
(Negative) 
3 
 Citrobacter amalonaticus 
(Negative) 
1 
 Achromobacter xylosoxidans 
(ESBL) 
1 
Check-Points Assay Failed Extraction 
(Multiple attempts) 
Acinetobacter baumannii 1 
Not Evaluated – Chromosomally-encoded 
carbapenemase 
Aeromonas spp. 2 
Not Evaluated  - Received whole genome 
sequencing (Results pending) 
Citrobacter freundii, 
Escherichia coli (co-colonized 






Figure 2.3. Decision tree for Predicting CRO Perirectal Colonization at Hospital Unit Admission. Gray-shaded terminal nodes 
indicate that the tree would classify patients as CRO-colonized, and accompanying percentages reflect the probability that patients 






Figure 2.4. Receiver Operating Characteristic (ROC) Curves for Multivariable Logistic 
Regression Models Predicting CRO and CPO Colonization at Unit Admission, Incorporating the 
Five Most Predictive Variables Identified in Random Forests Analysis. 
 
A). Receiver operating characteristic (ROC) curve for a multivariable logistic regression model with the outcome of 
carbapenem-resistant organism (CRO) colonization at unit admission and five independent variables: CRO-positive 
culture in the prior six months, total days of hospitalization in the prior six months, Elixhauser severity of illness 
score, total defined daily dose (DDD)-standardized doses of antibiotics with Gram-negative coverage in the prior 
three months, and total DDD-standardized doses of immunosuppressive therapy in the prior three months. Area 
under the curve (AUC) of 0.62; B). Corresponding ROC curve for the outcome of CPO colonization and five 
independent variables: CRO-positive culture in the prior six months, Elixhauser severity of illness score, total DDD-
standardized doses of antibiotics with Gram-negative activity in the prior three months, time from hospital-to-unit 




Figure 2.5. Variable Importance Plot of Most Predictive Variables for CRO Colonization and 
Corresponding Logistic Regression Output 
 
 
A). Random forests-generated variable importance plot ranking the ten most predictive variables for CRO 
colonization; B). Output from multivariable logistic regression analysis incorporating the top five, non-collinear 








Figure 2.6. Variable Importance Plot of Most Predictive Variables for CPO Colonization and 
Corresponding Logistic Regression Output 
 
 
A). Random forests-generated variable importance plot ranking the ten most predictive variables for CPO 
colonization; B). Output from multivariable logistic regression analysis incorporating the top five, non-collinear 









Supplementary Table S.2.1.  Performance Metrics of CART Decision Trees for Predicting CRE 
Colonization at Unit Admission 
 Raw (No Tuning) Tuned to Increase 
Sensitivity 
No. of Included Variables 1 12 
Sensitivity 5.8% 70.2% 
Specificity 99.9% 72.3% 
Positive Predictive Value (PPV) 64% 10% 
Negative Predictive Value (NPV) 96% 98% 
C-Statistic 0.53 0.76 
C-Statistic in Random Forests (RF) 
Analysis 
0.60 0.60 





Supplementary Figure S.2.1.  Decision tree for Predicting CRO Perirectal Colonization at 
Hospital Unit Admission, Fit with 50% Priors to Up-Weight Tree Sensitivity. Gray-shaded 
terminal nodes indicate that the tree would classify patients as CRO-colonized, and 
accompanying percentages reflect the probability that patients assigned to a given terminal 
node are CRO-positive. Terminal node numbering is included in parentheses. The tree 
possessed a sensitivity of 61.8%, a specificity of 70.4%, a positive predictive value of 14.5%, and 
a negative predictive value of 95.8%. Its C-statistic was 0.70, and its C-statistic following random 








Supplementary Figure S.2.2.  Decision tree for Predicting CPO Perirectal Colonization at Hospital Unit Admission, Fit with 10% 
Priors to Up-Weight Tree Sensitivity. Gray-shaded terminal nodes indicate that the tree would classify patients as CPO-colonized, 
and accompanying percentages reflect the probability that patients assigned to a given terminal node are CPO-positive. Terminal 
node numbering is included in parentheses. The tree possessed a sensitivity of 47.2%, a specificity of 99.1%, a positive predictive 






Supplementary Table S.2.2.  Performance Metrics of CART Decision Trees for Predicting CRO 
and CPO Colonization at Unit Admission, Restricted to First Unique-Patient Admission 
Encounters During the Study Period.* 
 CRO Decision Tree CPO Decision Tree 
No. of Outcomes (N=2165) 141 20 
No. of Included Variables 3 0 (Failed to Branch) 
Sensitivity 8.5% NA 
Specificity 99.8% NA 
Positive Predictive Value (PPV) 75% NA 
Negative Predictive Value (NPV) 94% NA 
C-Statistic 0.55 0.50 
* Number of first, unique-patient encounters during the study period equals 2165. 











Sensitivity Analysis Restricting to CPO Isolates with Molecularly-Confirmed Carbapenemases 
In order to address possible outcome misclassification, for the outcome of CPO colonization we 
refit a decision tree and performed random forests analysis restricting to CPO isolates with 
molecularly-confirmed carbapenemases. Of the 36 CPO-positive swabs, 22 were positive for 
one or more carbapenemases on the Checkpoints assay (representing 23 isolates, due to CP-
CRE co-colonization on one swab). A decision tree fit to this data failed to branch, indicating 
that no variables were sufficiently predictive for this outcome. We also refit a decision tree with 
10% priors in order to increase tree sensitivity. This tree possessed a C-statistic of 0.94 and 
included 14 variables, evidencing that it was overfit. In random forests analysis (no adjustment 
of priors), the C-statistic was 0.68, similar to the value for the primary CPO outcome (C-statistic 
0.70). Taken together, the evidence indicates that restricting the CPO outcome to swabs 
possessing molecularly-confirmed carbapenemases did not materially improve, or in some 
cases reduced, model performance.  
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Background.  Timely identification of extended-spectrum β-lactamase (ESBL) bacteremia can 
improve clinical outcomes while minimizing unnecessary use of broad-spectrum antibiotics, 
including carbapenems. However, most clinical microbiology laboratories currently require at 
least 24 additional hours from the time of microbial genus and species identification to confirm 
ESBL production. Our objective was to develop a user-friendly decision tree to predict which 
organisms are ESBL-producing, to guide appropriate antibiotic therapy. 
 
Methods.  We included patients ≥18 years of age with bacteremia due to Escherichia 
coli or Klebsiellaspecies from October 2008 to March 2015 at Johns Hopkins Hospital. Isolates 
with ceftriaxone minimum inhibitory concentrations ≥2 µg/mL underwent ESBL confirmatory 
testing. Recursive partitioning was used to generate a decision tree to determine the likelihood 
that a bacteremic patient was infected with an ESBL-producer. Discrimination of the original 
and cross-validated models was evaluated using receiver operating characteristic curves and by 
calculation of C-statistics. 
 
Results.  A total of 1288 patients with bacteremia met eligibility criteria. For 194 patients (15%), 
bacteremia was due to a confirmed ESBL-producer. The final classification tree for predicting 
ESBL-positive bacteremia included 5 predictors: history of ESBL colonization/infection, chronic 
indwelling vascular hardware, age ≥43 years, recent hospitalization in an ESBL high-burden 
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region, and ≥6 days of antibiotic exposure in the prior 6 months. The decision tree's positive 
and negative predictive values were 90.8% and 91.9%, respectively. 
 
Conclusions.  Our findings suggest that a clinical decision tree can be used to estimate a 
bacteremic patient's likelihood of infection with ESBL-producing bacteria. Recursive partitioning 
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Extended-spectrum β-lactamase (ESBL)-producing bacteria represent a serious clinical and 
public health challenge [1]. ESBL-producing bacteria can hydrolyze most broad-spectrum β-
lactam antibiotics, with the exception of carbapenems [2]. Serious infections, including 
bacteremia, with ESBL-producing organisms are associated with higher morbidity and mortality 
relative to infections with more susceptible organisms [3, 4]. Existing data suggest that this 
disparity results at least in part from delayed initiation of appropriate therapy, as many empiric 
antibiotic regimens have limited activity against ESBL-producers [5, 6]. While carbapenems 
remain effective against ESBL-producing organisms, they should be used judiciously, because 
indiscriminate empiric carbapenem use may select for carbapenem-resistant 
Enterobacteriaceae [7, 8]. 
 
Rapid diagnostics to identify various β-lactamase genes are becoming increasingly available to 
reduce the time between Gram-stain results and resistance mechanism identification, but such 
assays can be resource-intensive and, thus, are currently not widely used in clinical 
microbiology laboratories. Additionally, commonly used molecular-based Gram-negative panels 
do not include, or at most only identify one of, the ESBL gene groups [9]. Consequently, 
clinicians must select empirical antibiotic treatment for patients with Gram-negative 
bacteremia without knowing whether the causative organism is ESBL-producing, while 
balancing the risk of ineffective therapy against unnecessarily broad antibiotic treatment. This 
delay in selecting appropriate antibiotic treatment can lead to poor patient outcomes [4].  
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Statistical models for predicting ESBL-producing infections can help to address current 
diagnostic limitations.   
 
Numerous recent investigations have used multivariable logistic regression models to identify 
exposures independently associated with ESBLs (e.g., previous antibiotic therapy, presence of 
an indwelling urinary catheter, etc.) [10-12]. Although valuable for exploring potential risk 
factors driving the emergence of ESBL-producing bacteria, these approaches do not help 
clinicians readily synthesize or decide how to prioritize multiple risk factors. Conversion of 
logistic regression coefficients into a risk score model addresses some of these concerns, but 
these models may be cumbersome to implement depending upon the number of included 
variables and complexity of end-user calculations.   
 
Recursive partitioning is a form of machine learning rarely utilized in the clinical antibiotic 
resistance literature that may be helpful as a predictive modeling tool in these circumstances 
[13, 14]. Its output, a decision tree algorithm, has several practical advantages, including 
simplicity and intuitive interpretation. Our objective was to develop a user-friendly decision 
tree to predict, at the time of organism identification from a blood culture, which bacteremias 
are due to ESBL-producers in order to guide appropriate antibiotic therapy.    
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Setting and Participants   
This study included patients aged 18 years of age and older hospitalized at The Johns Hopkins 
Hospital with bloodstream isolates growing Klebsiella pneumoniae, Klebsiella oxytoca, or 
Escherichia coli from October 2008 to March 2015. Records were identified from The Johns 
Hopkins Hospital clinical microbiology laboratory database. Only first episodes of bacteremia 
with the above organisms for a given patient were included. This study was approved by the 
Johns Hopkins University School of Medicine Institutional Review Board, with a waiver of 
informed consent.  
 
Clinical Data Collection  
Patient data were extracted from all available inpatient and outpatient medical records from 
facilities within the Johns Hopkins Health System, as well as from medical records for patients 
who previously received medical care at institutions in the EPIC Care Everywhere Network 
(https://www.epic.com/CareEverywhere/), into a REDCap database. The EPIC Care Everywhere 
Network is a secure health information exchange that allows clinicians to securely view 
previous patient medical information from a large number of inpatient and outpatient 
healthcare networks throughout the United States. The following patient data were collected, 
with all information based on the time period prior to day one of bacteremia, defined as the 
day the blood culture was obtained: (a) demographic data, (b) pre-existing medical conditions, 
(c) source of bacteremia, (d) indwelling hardware (e.g, orthopedic hardware, urology hardware, 
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central venous catheters, grafts, etc.), (d) multidrug-resistant organism colonization or infection 
(multidrug-resistant Pseudomonas aeruginosa, multidrug-resistant Acinetobacter baumannii, 
ESBLs, carbapenem-resistant Enterobacteriaceae, vancomycin-resistant Enterococcus species, 
and methicillin-resistant Staphylococcus aureus) within the previous 6 months [15], (e) days of 
gram-negative active inpatient and outpatient antibiotic therapy (extended-spectrum 
penicillins, third- and fourth-generation cephalosporins, aztreonam, carbapenems, 
aminoglycosides, and fluoroquinolones) within the previous 6 months, (f) days of stay in any 
healthcare facility (outpatient procedures were assigned “1 day of stay”), (g) hospitalization in 
another country in the previous 6 months, and (h) residence in a long term care facility or 
nursing home within the previous 6 months. Patients who were hospitalized in another country 
were separated into high-burden and low-burden ESBL regions. “High-burden” included the 
following regions: Latin America (excluding the Caribbean); the Middle East (including Egypt); 
South Asia; China; and the Mediterranean [16, 17].   
 
Microbiology Methods 
Bloodstream isolates of E. coli, K. pneumoniae, and K. oxytoca were processed at The Johns 
Hopkins Hospital Microbiology Laboratory according to standard operating procedures. 
Antibiotic susceptibility data were determined by the BD Phoenix Automated System™ (BD 
Diagnostics, Sparks, Maryland). Organisms with minimum inhibitory concentrations (MICs) ≥2 
μg/mL for ceftriaxone underwent further confirmation for ESBL production. A decrease of >3 
doubling dilutions in the MIC for a third-generation cephalosporin tested in combination with 4 
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μg/mL of clavulanic acid, versus its MIC when tested alone, was used to confirm ESBL status. 
There were no changes in the method of organism identification, antibiotic susceptibility 
testing, or ESBL confirmatory testing during the study period.   
 
Statistical Methods 
Data Analysis and Logistic Regression.  Descriptive statistics for patient variables were 
calculated using mean (standard deviation [SD]), median (range or interquartile range), or 
frequency count (percentage), as appropriate. The relationship between each study covariate 
and ESBL status was evaluated using univariable logistic regression, as summarized by odds 
ratios and corresponding 95% confidence intervals. Final multivariable logistic regression 
models were derived using stepwise variable selection with backward elimination at an alpha 
level of 0.05 (a common, though of debated validity, approach in the literature) and lasso 
regression at the value of the shrinkage parameter that minimized misclassification error in the 
cross-validated model [18]. Lasso regression was performed using the ‘glmnet’ (Lasso and 
Elastic-Net Regularized Generalized Linear Models) package, version 2.0-2, in the R statistical 
package (version 3.0.3). 
 
Decision Tree Derivation.  We built a  decision tree to predict whether a patient’s bacteremia 
was due to an ESBL-producer applying the classification and regression tree (CART) algorithm 
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[14] on  a dataset including all study variables using the ‘rpart’ (Recursive Partitioning and 
Regression Trees) package, version 4.1-9, in R.  
 
Briefly, a tree was built using the following process: (1) identification of the single variable that, 
when used to split the dataset into two groups (“nodes”), best minimized impurity of ESBL 
status in each daughter node, according to the Gini impurity criterion [14, 19]; (2) repetition of 
the partitioning process within each daughter node and subsequent generations of nodes 
(“recursive partitioning” or “branching”); and (3) cessation at “terminal” nodes when no 
additional variables achieve further reductions in node impurity. Terminal nodes in binary 
recursive partitioning trees predict ESBL status categorically but, by evaluating the node 
impurity, also offer associated probabilities.  
 
Decision Tree Validation.  We internally validated the performance of our model using the 
leave-one-out cross-validation (LOOCV) method [19].  We evaluated the discrimination of the 
original and cross-validated models through the generation of receiver operating characteristic 
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A total of 1288 Johns Hopkins Hospital patients with bacteremia due to E. coli (56%),  K. 
pneumoniae (40%), or K. oxytoca (4%), spanning the period from October 2008 to March 2015, 
met eligibility criteria. For 194 patients (15%), bacteremia was due to a confirmed ESBL-
producer.  
 
Patient and microbial characteristics are presented in Table 3.1. Evaluating the full cohort, 
patients were a mean age of 55 years (SD, 16.4). Twenty-five percent of patients had a history 
of prior colonization or infection with a multidrug-resistant organism within the preceding six 
months. In the six months prior to bacteremia, patients had been hospitalized for a mean of 
13.7 (SD, 20.3) days (excluding the current hospitalization) and had received a mean of 11.6 
(SD, 20.2) days of antibiotic therapy. The majority of bacteremias originated from the urinary 
tract (37%), followed by intra-abdominal (24%), catheter-related (16%), and biliary (14%) 
sources.   
 
Among patients with ESBL-positive bacteremia, 43% received chemotherapy within the prior six 
months, and the majority (68%) had chronic indwelling vascular hardware present at the time 
of bacteremia onset. Twenty-five percent had at least one overnight stay in a hospital in an 
ESBL high-burden region within the prior six months. Figure 3.1 reflects the distribution of ESBL-
positive bacteremia cases by geographic region.  
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In univariable logistic regression analysis, a large proportion of collected data (25 study 
variables) were significantly associated with ESBL-positive bacteremia at an alpha level of 0.05, 
Table 1. The most strongly associated variables included prior history of an ESBL (odds ratio 
(OR) 51.45, 95% CI: 29.11 – 90.93) or carbapenem-resistant Enterobacteriaceae (OR 23.01, 95% 
CI: 2.56 – 206.99) colonization/infection, and recent international hospitalization in a high-
burden region (OR 30.47, 95% CI: 15.83 – 58.64). Final multivariable models derived using 
stepwise variable selection and lasso regression included 14 and 16 variables, respectively, 
Table 3.1.   
 
Decision Tree 
Using binary recursive partitioning, the final classification tree for predicting ESBL-positive 
bacteremia included five study variables (Figure 3.2). The first question in the tree, also called 
the root node, asked (1) Does the patient have a history of ESBL colonization or infection in the 
previous six months?  In classification trees, positive or “yes” responses branch to the right. If 
“yes,” the second question queried (2) Did the patient have chronic indwelling vascular 
hardware (defined as a dialysis or central venous catheter) at the time of bacteremia onset?  
Those patients meeting these criteria were classified as ESBL-positive (Terminal node 6) with an 
associated 92% probability. In patients with an ESBL history but lacking indwelling vascular 
hardware, the tree questioned (3) Is the patient aged 43 years or older?  (Based upon model-
derived dichotomization at 43 years). If “yes,” patients were classified as ESBL-positive 
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(Terminal node 5, 81% probability) and if “no” were classified as ESBL-negative (Terminal node 
4, 75% probability).  
 
For those 1188 patients lacking a history of prior ESBL infection or colonization (question 1), the 
root node branched left. The tree then asked (2) Has the patient been hospitalized in an ESBL 
high-burden region for one or more nights in the prior six months?  If “yes,” (3) Has the patient 
received six or more days of antibiotics in the prior six months? (Based upon model-derived 
dichotomization at six days). Those patients meeting these criteria were classified as ESBL-
positive (Terminal node 3) with 100% probability. Patients who had been internationally 
hospitalized in a high-burden region but had not received at least six days of antibiotics were 
classified as ESBL-negative (Terminal node 2, 63% probability). Finally, patients who both lacked 
a prior ESBL history and recent high-risk international hospitalization were classified as ESBL-
negative, constituting the majority of the dataset (Terminal node 1, 93% probability, 1152 
patients).  
 
The overall tree possessed a sensitivity of 51.0%, a specificity of 99.1%, and a kappa value 
(reflecting chance-corrected agreement) of 0.61. The positive and negative predictive values 
were 90.8% and 91.9%, respectively. Incorporating outcome probabilities based on terminal 
node impurities, the C-statistic for the final tree trained on the full dataset was 0.77 and 0.77 
following cross-validation. Of the 194 patients with ESBL bacteremia, 35% (68) received empiric 
carbapenem therapy within six hours after genus and species identification. Utilization of the 
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decision tree would have increased ESBL case detection during the empiric treatment window 
by approximately 50%. The decision tree identified one-third of the original 68 patients, as well 
as an additional 78 ESBL cases, as “ESBL-positive” and warranting empiric therapy with agents 
covering ESBL-producing bacteria.  
 
Sensitivity Analyses 
Approximately 45% (86/194) of ESBL-positive bacteremia patients were classified in Terminal 
node 1 as ESBL-negative, compromising decision tree sensitivity. We performed sensitivity 
analyses on the subset of 1152 patients who lacked the two strongest study risk factors of prior 
ESBL infection or colonization history and recent international hospitalization in an ESBL high-
burden region. We first re-fit a classification tree to this subset of data, and the resulting tree 
failed to branch (sensitivity 0%, C-statistic 0.50), consistent with truncation at terminal node 1 
in the original tree. We also performed random forest analyses, a methodology that is less 
easily interpretable than binary recursive partitioning because it generates many bootstrapped 
classification trees, but that yields estimates of the most important classification variables [13, 
20]. In random forest analysis on the data subset, no variables were strongly predictive of ESBL-
positive bacteremia. An ROC curve generated from a logistic regression including the three 
most important variables yielded a C-statistic of 0.53.  As definitions of “high burden” may 
reasonably differ, we also modeled international hospitalization to include all of Asia, as well as 
to include all countries without region restriction. Discriminatory performance remained similar 
to the original model in both analyses (C-statistics both 0.78).   
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Timely identification of ESBL bacteremia can improve clinical outcomes while minimizing the 
unnecessary use of broad-spectrum antibiotics.  Yet despite advances in rapid diagnostics, most 
clinical microbiology laboratories still require at least 24 additional hours from the time of 
organism identification to confirmation of ESBL production. Empirically treating serious Gram-
negative infections therefore remains a clinical challenge and leaves clinicians to balance the 
risks of ineffective agents against unnecessarily broad empiric antibiotic therapy on an ad-hoc 
basis. A user-friendly clinical decision tree to determine a bacteremic patient’s likelihood of 
infection with an ESBL-producing bacteria could assist clinicians with selecting appropriate 
empiric treatment at the time of organism identification. 
 
From a dataset of more than 30 demographic and clinical variables, we developed a decision 
tree with five predictors: prior history of ESBL colonization or infection; presence of chronic 
indwelling vascular hardware; age (model-derived dichotomization at 43 years); recent 
hospitalization in an ESBL high-burden region; and total antibiotic exposure in the prior six 
months (model-derived dichotomization at six days). Patients classified as ESBL-positive by the 
tree were 90.8% likely to be true ESBL cases (PPV), and patients classified as negative were 
91.9% likely to be true ESBL-negative cases (NPV).  
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Our findings highlight the utility of recursive partitioning as a predictive modeling tool. In 
multivariable logistic regression, a high number of variables remained associated with ESBL-
positive bacteremia, complicating efforts to translate statistical findings into practical 
application. Converting logistic regression coefficients into a risk score may have partially 
addressed this concern, but the resulting model would likely have been cumbersome to 
implement at the bedside. In contrast, a decision tree is generally intuitive and does not require 
tallying across variables. Moreover, recursive partitioning possesses attractive methodological 
features, including the ability to accommodate higher-order variable interactions and to 
generate automatic breakpoints for continuous variables [14, 21]. Perhaps most importantly, 
although decision trees yield categorical predictions (generally decided by majority rule in the 
terminal node), the strength of these predictions is quantifiable through terminal node 
impurities. As such, like risk scores, decision trees remain flexible to differing risk-aversion 
attitudes. For example, in a septic patient with a predicted 25% probability of ESBL-positive 
infection, it may be reasonable to prescribe empiric carbapenem therapy despite decision tree 
classification as ESBL-negative. As with any methodological tool, classification trees can help to 
guide, but cannot replace, clinical judgment. The comfort level of clinicians, the clinical 
appearance of patients, and institutional treatment guidelines are necessary to fine-tune 
decisions. 
 
Of note, a subset of ESBL-positive cases lacked a prior ESBL history and recent international 
hospitalization in an ESBL high-burden region and were classified by the tree as ESBL-negative. 
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Additional analyses suggested that no study variables were strongly discriminatory among this 
subset of patients. The poor predictive nature of healthcare-associated variables within this 
patient subset may suggest a high proportion of community-acquired ESBL infections. Indeed, 
although risk factors for ESBLs have traditionally focused on the healthcare setting, increasing 
reports describe the community as an important ESBL reservoir [22-26], with documented 
person-to-person transmission in the community and in households (predominantly E. coli 
sequence type 131) [27-29]. There is also evidence that livestock operations and food-supplying 
animals may be a source of ESBL-producing infections [30-33]. Additional information on 
community-associated exposures and isolate strain-type were unavailable for these patients, 
unfortunately precluding further exploration of this hypothesis.   
 
Our study has several limitations. First, this was a single-center study, and our results should be 
validated in other cohorts. Our results may not be generalizable to patients in other 
populations, particularly in high ESBL prevalence regions. Second, recent international 
hospitalization was evaluated through a “Yes/No” nursing intake questionnaire, which despite 
hospital policy to inquire of all patients may have been inconsistent during the study period. 
Selective questioning of patients perceived as higher risk could have artificially inflated the 
importance of this exposure. However, the association remained significant across calendar 
years, including later years when we expected greater policy compliance. Third, we recognize 
that individuals may define “high burden” international regions differently and that ESBL 
geographic prevalence changes over time. Sensitivity analyses yielded similar discriminatory 
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performance under varied regional definitions, however, suggesting that the model was robust 
to these differences. Fourth, in order to reduce outcome misclassification, we restricted our 
study to E. coli and Klebsiella spp., as Centers for Disease Control and Prevention screening 
methodology to test for ESBL production is limited to these organisms. As a result, our tree’s 
performance has only been validated from the point of genus and species identification of 
these common ESBL-producing organisms. If our tree is validated by others and evaluated in 
broader clinical practice, however, it may be reasonable at Gram-negative confirmation to 
initiate carbapenem therapy in patients at high predicted risk of ESBL infection. Finally, despite 
our best attempt to gather detailed previous clinical data on all patients across health networks 
in the EPIC Care Everywhere network, due to the retrospective nature of this study there was 
likely missing data that could lead to exposure misclassification, although we would not expect 
it to be differential by ESBL status.  In light of the decision tree’s intended real-world use, 
however, its performance under the practical constraints of missing data is arguably relevant. 
As the use of electronic health records that interface across institutions becomes more 
widespread, these challenges may lessen.   
 
Overall, our findings suggest that a clinical decision tree can be used to estimate, at the time of 
Gram-negative organism identification, a bacteremic patient’s likelihood of infection with an 
ESBL-producing bacteria.  These predictions may assist empiric treatment decisions, in order to 
optimize clinical outcomes while reducing administration of overly broad antibiotic agents that 
can select for further resistance emergence. The machine learning methodology relied upon in 
Clinical Infectious Diseases® 2016;63(7):896–903 © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of 
America. All rights reserved. 
70 
 
this study has been rarely utilized in the clinical infectious diseases literature but may offer a 
practical, user-friendly output for addressing important diagnostic questions.  
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Table 3.1.  Description of Patient and Microbial Characteristics in a Cohort of Adult Patients 
with Escherichia coli and Klebsiella species Bacteremia, by Extended-Spectrum Beta-
Lactamase Status 












 N = 194 N = 1094   
Demographics     
Age 51 ± 18.4 56 ± 15.9 0.98 (0.97 – 
0.99) 
<0.001 
Male sex 113 (58%) 590 (54%) 1.18 (0.87 – 
1.61) 
0.23 
Race/Ethnicity     
   White 85 (44%) 523 (48%) Reference  Reference 
   Black 49 (25%) 458 (42%) 0.66 (0.45 – 
0.96) 
0.03 
   Latino 11 (6%) 39 (4%) 1.74 (0.86 – 
3.52) 
0.13 
   Asian 25 (13%) 38 (3%) 4.05 (2.33 – 
7.05) 
<0.001¥ θ 





    
Human Immunodeficiency 
Virus positive 
5 (3%) 53 (5%) 0.52 (0.21 – 
1.32) 
0.17 
Chemotherapy within previous 
6 months 





8 (4%) 65 (6%) 0.68 (0.32 – 
1.44) 
0.32 
Solid organ transplantation 29 (15%) 145 (13%) 1.15 (0.75 – 
1.77) 
0.53 
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Hematopoeitic stem cell 
transplantation 
12 (6%) 48 (4%) 1.44 (0.75 – 
2.76) 
0.28 
End-stage liver disease 17 (9%) 76 (7%) 1.29 (0.74 – 
2.23) 
0.37 
End-stage renal disease 
requiring dialysis 
15 (8%) 81 (7%) 0.96 (0.62 – 
1.48) 
0.84 
Congestive heart failure 
(ejection fraction <40) 
16 (8%) 81 (7%) 1.12 (0.64 – 
1.97) 
0.68 
Structural lung disease2 19 (10%) 44 (4%) 2.60 (1.48 – 
4.54) 
0.001¥ θ 
Indwelling Hardware at the 
Onset of Bacteremia 
    
Biliary stent 18 (9%) 119 (11%) 0.84 (0.50 – 
1.41) 
0.51 
Gastrointestinal feeding tube 25 (13%) 57 (5%) 2.69 (1.64 – 
4.43) 
<0.001¥ θ 
Nephrostomy tubes and/or 
Foley catheter 
45 (23%) 113 (10%) 2.62 (1.78 – 
3.86) 
<0.001¥ θ 
Chronic vascular hardware3 131 (68%) 461 (42%) 2.86 (2.07 – 
3.95) 
<0.001¥ θ 




Organism History (Colonization 
or Infection <6 Months) 
    
Vancomycin-resistant 
Enterococcus species. 















4 (2%) 1 (<1%) 23.01 (2.56 – 
206.99) 
0.01¥ θ 
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2 (1%) 1 (<1%) 11.39 (1.03 – 
126.18) 
0.05 
Recent Antibiotic Exposure (<6 
Months) 
    
Days of extended-spectrum 
penicillin therapy 
6.6 ± 11.2 3.5 ± 8.0 1.03 (1.02 – 
1.05) 
<0.001 
Days of third and fourth-
generation cephalosporin 
therapy 
4.9 ± 8.2 2.1 ± 4.8 1.07 (1.04 – 
1.09) 
<0.001θ 
Days of aztreonam therapy 0.3 ± 1.5 0.2 ± 1.9 1.02 (0.95 – 
1.10) 
0.61 
Days of carbapenem therapy 5.0 ± 9.0 1.8 ± 6.2 1.05 (1.03 – 
1.07) 
<0.001 
Days of fluoroquinolone 
therapy 
3.1 ± 6.8 2.2 ± 6.8 1.02 (1.00 – 
1.04) 
0.10 
Days of aminoglycoside therapy 1.3 ± 4.7 0.3 ± 1.9 1.11 (1.05 – 
1.17) 
<0.001¥ θ 
Total days of antibiotics 
(combined) 
21.0 ± 25.6 10.0 ± 18.6 1.02 (1.01 – 
1.03) 
<0.001 
Total Days of Hospitalization in 
the 6 Months Prior to Current 
Hospitalization 
23.1 ± 26.7 12.0 ± 18.5 1.02 (1.01 – 
1.03) 
<0.001 
Duration of Time from 
Hospital Admission to Positive 
Blood Culture (days) 




Healthcare Exposure (<6 
Months) 
    
At least one overnight stay in a 
healthcare facility  in an ESBL 
high-burden region5 
49 (25%) 12 (1%) 30.47 (15.83 – 
58.64) 
<0.001¥ θ 
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Other High-Risk Healthcare 
Exposures (<6 Months) 
    
Long-term acute care facility 
residence 
17 (9%) 22 (2%) 4.68 (2.44 – 
8.99) 
<0.001¥ θ 
Nursing home residence 6 (3%) 16 (2%) 2.15 (0.83 – 
5.57) 
0.12 
Source of Bacteremia     
Urinary tract  65 (34%) 407 (38%) Reference Reference 
Skin and soft tissue  4 (2%) 43 (4%) 0.59 (0.21 – 
1.71) 
0.33θ 
Biliary 16 (8%) 168 (15%) 0.60 (0.34 – 
1.07) 
0.08 
Intra-abdominal  35 (18%) 271 (25%) 0.80 (0.52 – 
1.25) 
0.33 
Catheter-related  57 (29%) 143 (13%) 2.48 (1.66 – 
3.72) 
<0.001¥ θ 
Bone and/or joint 1(<1%) 10(1%) 0.62 (0.08 – 
4.95) 
0.66 




1Excluding chemotherapy or immunosuppression for solid organ transplants; 2Chronic 
obstructive pulmonary disease, emphysema, tracheostomy-dependent; 3central venous 
catheter or dialysis catheter; 4http://www.cdc.gov/nhsn/pdfs/ps-analysis-
resources/phenotype_definitions.pdf;5Colombia(1), Costa Rica (1), El Salvador (2), Honduras (4), 
Mexico (3), Panama(1), China (3), Iran(1), Jordan(1), Kuwait(4), Qatar(4), Saudi Arabia(10), UAE 
(5), Bangladesh (2), India (7), Pakistan (5), Egypt (2), Greece (2), Turkey (3). An additional eight 
and nine ESBL-positive and ESBL-negative patients, respectively, were hospitalized 
internationally in a non-high-burden region in the six months preceding bacteremia; ¥ - 
Significant in multivariable analysis using stepwise selection with backwards elimination at an 
alpha level 0.05. Among variables that were significant in multivariable analysis, one variable, a 
history of multidrug-resistant Pseudomonas species, demonstrated qualitative confounding 
(univariable and multivariable odds ratios 1.62 and 0.08, respectively); θ - Retained in final 
multivariable model using lasso regression. 
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Figure 3.1.  Distribution of recent international healthcare exposure among ESBL-positive cases. 57 of 194 ESBL-positive patients 
had a recent international healthcare exposure, defined as hospitalization for one or more nights outside of the United States in the 
six months preceding ESBL bacteremia. 
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Figure 3.2.  Clinical decision tree to predict a bacteremic patient’s likelihood of infection with 
an ESBL-producing bacteremia at the time of organism genus and species identification. Gray-
shaded terminal nodes indicate that the tree would classify patients as ESBL-positive,  and 
accompanying percentages (derived from terminal node impurities) reflect the probability that 
patients assigned to a given terminal node are ESBL-positive.  Terminal node numbering, 1 
through 6, is included in parentheses.  
 
* Latin America (excluding the Caribbean); the Middle East (including Egypt); South Asia; China; 
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Background.  Timely identification of multidrug-resistant Gram-negative infections, including 
extended-spectrum β-lactamase (ESBL)-producing organisms, remains a clinical challenge. 
Statistical models for predicting drug resistance can offer utility where rapid diagnostics are 
unavailable or resource-impractical. Logistic regression-derived risk scores are common in the 
clinical infectious disease literature. Machine learning-derived decision trees are an alternative 
approach for developing clinical decision support tools. Our group previously reported on a 
decision tree for predicting ESBL bloodstream infections. Our objective in the current study was 
to develop a risk score from the same ESBL dataset to compare these two methods and to offer 
general guiding principles for when clinicians might consider each approach. 
 
Methods.  In a dataset of 1,288 patients with Escherichia coli or Klebsiella spp. bacteremia, we 
generated a clinical risk score to predict the likelihood that a bacteremic patient was infected 
with an ESBL-producer. Discrimination (original and cross-validated models) was evaluated 
using receiver operating characteristic curves and C-statistics. Risk score and decision tree 
performance was compared, and their practical and methodological attributes were reviewed.  
 
Results.  194 patients (15%) were infected with ESBL-producing bacteremia. The clinical risk 
score included 14 variables, compared to the decision tree’s five. The score and decision tree’s 
positive and negative predictive values were similar (>90%), but the score’s C-statistic (0.87) 





Conclusions.  A decision tree and risk score performed similarly for predicting ESBL infection. 
However, the decision tree was more user-friendly with fewer variables, while the risk score 






Multidrug-resistant Gram-negative (MDRGN) organisms represent a growing clinical threat. 
These bacteria can spread rapidly among vulnerable hospitalized populations, and MDRGN 
infections are associated with significant morbidity and mortality [1, 2]. Timely identification 
can limit nosocomial transmission and improve patient outcomes by facilitating prompt 
initiation of appropriate treatment [3, 4]. However, rapid diagnostics that can be readily 
incorporated into routine laboratory workflows are limited or lacking for many MDRGNs, posing 
clinical and epidemiological challenges.  
 
Extended-spectrum β-lactamase (ESBL)-producing bacteria, which can hydrolyze most β-lactam 
antibiotics other than carbapenems, are a representative example. Currently there is no Clinical 
and Laboratory Standards Institute (CLSI)-endorsed phenotypic method for ESBL detection [5]. 
Although molecular methods for identifying ESBL genes are commercially available, these 
assays do not include a comprehensive list of known ESBL genes and would require frequent 
panel updates to detect emerging ESBLs [6, 7]. Molecular diagnostics can also be resource-
intensive and are often not cost-effective for laboratories in regions where ESBL prevalence is 
low, and are cost-prohibitive for developing areas of the world where ESBL prevalence is high.    
 
Statistical models for identifying MDRGN infections can provide important information in 
settings where rapid diagnostics are unavailable or resource-impractical. Logistic regression-




regression tree (CART) analysis or “recursive partitioning,” a form of machine learning, is an 
alternative approach for developing this type of clinical decision support tool. Our group 
previously reported on a CART decision tree for predicting ESBL bloodstream infections to guide 
empiric therapy [8]. There has been interest in evaluating whether a risk score derived from the 
same population could achieve greater predictive accuracy while remaining sufficiently simple 
to incorporate into clinical practice.  
 
We present a case study of the development of a risk score from the same ESBL dataset as our 
original decision tree to compare the predictive accuracy of these two methods, to illustrate the 
advantages and disadvantages of logistic regression risk scores versus CART decision trees, and 
to offer general guiding principles for when clinical researchers might consider one prediction 
approach versus the other.  
 
METHODS 
Cohort   
The full description of the cohort has been previously reported [8]. Briefly, the study included 
adults hospitalized at The Johns Hopkins Hospital with bacteremia due to Escherichia coli or 
Klebsiella species, from 2008 to 2015. Only the first episode of bacteremia per patient was 
included. Escherichia coli or Klebsiella spp. with ceftriaxone minimum inhibitory concentrations 




the MIC for a third-generation cephalosporin tested in combination with 4 μg/mL of clavulanic 
acid, versus its MIC when tested alone, was used to confirm ESBL status.  
 
Patient data were collected via manual chart review from all available inpatient and outpatient 
medical records from facilities within the Johns Hopkins Health System, as well as from medical 
records for patients who previously received medical care at institutions in the Epic Care 
Everywhere Network (www.epic.com/CareEverywhere/). Patient data collected, which was 
based on the time period prior to day one of bacteremia (defined as the date the initial blood 
culture was collected), included the following: (a) demographic data; (b) pre-existing medical 
conditions; (c) presumptive source of bacteremia (e.g., catheter, pneumonia); (d) indwelling 
hardware; (e) multidrug-resistant organism (MDRO) colonization or infection (multidrug-
resistant Pseudomonas aeruginosa, multidrug-resistant Acinetobacter baumannii, ESBL-
producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, vancomycin-
resistant Enterococcus species, and methicillin-resistant Staphylococcus aureus) [9] in the prior 
six months; (f) days of gram-negative active antibiotic therapy in the prior six months; (g) length 
of stay in any healthcare facility in the prior six months; (h) post-acute care facility stay in the 
prior six months; and (i) hospitalization in another country in the prior six months (assessed by 
standard nursing intake questionnaire upon Johns Hopkins Hospital admission). International 
hospitalizations in the following regions were classified as ESBL “high-burden:” Latin America 
(excluding the Caribbean); the Middle East (including Egypt); South Asia; China; and the 





Statistical Methods   
Descriptive statistics, univariable analyses, and decision tree derivation and validation have 
been previously described [8]. Briefly, a tree was derived using the following process: (1) 
identification of the single variable that, when used to split the dataset into 2 groups (“nodes”), 
best separated ESBL-positive from ESBL-negative patients, according to the Gini impurity 
criterion [12, 13]; (2) repetition of this partitioning process in each daughter node and 
subsequent generations of nodes (“branching”); and (3) termination at “terminal” nodes 
(“leaves”) when no additional variables in the data sufficiently distinguished patients by their 
ESBL status. Terminal nodes in binary recursive partitioning trees predict ESBL status 
categorically but, by evaluating the node impurity (e.g., the mixture of ESBL-positive and ESBL-
negative patients), also offer associated probabilities. We internally validated the performance 
of our tree using the leave-one-out cross-validation method (LOOCV)[12] and evaluated the 
discrimination of the original and cross-validated models through the generation of receiver 
operating characteristic (ROC) curves and calculation of C-statistics. Decision tree analyses were 
performed using the rpart (Recursive Partitioning and Regression Trees) package, version 4.1–9, 
in R. 
 
To develop a risk score, continuous variables (e.g., age, antibiotic days) were first converted 
into ordinal categories in order to reduce complexity, given the score’s anticipated manual 




selection with backward elimination at an α level of 0.05 and lasso regression at the value of 
the shrinkage parameter that minimized misclassification error in the cross-validated lasso 
model. The most parsimonious model was selected for conversion to a risk score. To create 
points, regression coefficients were rescaled by dividing by the smallest final model coefficient 
and rounding to the nearest integer (with the exception of antibiotic therapy, which received 
0.25 points per week (up to a maximum of 1 point or ≥ 4 weeks), in order to simplify end-user 
calculations). Patient scores were calculated by summing their respective points (risk score 
model).   
 
For both the final multivariable regression model and the risk score model, discrimination was 
assessed with ROC curves and accompanying C-statistics (i.e., area under the curve). Risk score 
model calibration was evaluated by Hosmer-Lemeshow (HL) goodness-of-fit tests and graphical 
plots of observed proportion versus model-predicted ESBL probabilities by decile groups. 
Discrimination was internally validated with leave-one-out cross-validation (LOOCV). Risk score 
analyses were performed in Stata, version 13.0 (StataCorp, College Station, TX) and R. 
 
RESULTS 
Spanning the 2008 to 2015 time period, a total of 1,288 bacteremic patients met inclusion 
criteria, of whom 194 (15%) were ESBL-positive. Patient and microbial characteristics have been 





Risk Score   
Multivariable models derived using stepwise variable selection and lasso regression included 14 
and 16 variables, respectively, with full agreement on the first 14 variables. The simpler 
stepwise-derived model was selected for risk score development. Therefore, the final clinical 
risk score for predicting ESBL-positive bloodstream infection at the time of organism and genus 
identification included 14 variables, broadly categorizable into six groups (Figure 4.1):  
(A) Indwelling hardware on day of culture: Orthopedic hardware (2 points); chronic 
indwelling vascular hardware (1 point); nephrostomy tube or Foley catheter (2 points); 
gastrointestinal feeding tube (2 points). 
(B) Presumptive source of bloodstream infection: Catheter (2 points); pneumonia (2 points). 
(C) Patient characteristics: Structural lung disease (Chronic obstructive pulmonary disease, 
emphysema, or tracheostomy-dependency) (2 points); self-identification as Asian race 
(2 points). 
(D) Healthcare exposure within the previous 6 months: Post-acute care facility (2 points); ≥1 
night of international hospitalization in an ESBL high-burden region (5 points). 
(E) MDRGN colonization or infection within the previous 6 months: ESBL (6 points); 
carbapenem-resistant Enterobacteriaceae (CRE) (6 points); MDR Pseudomonas species (-
4 points).  
(F) Antibiotic exposure within the previous 6 months: Weeks of active gram-negative 




Patient scores ranged from -3 to 18.75, with a median score of 2 points (interquartile range: 0 
to 3.25). The C-statistic for the clinical risk score was 0.87 and 0.89 following cross-validation. 
The C-statistic for the multivariable logistic regression model was also 0.87 (Supplement 4.1). 
The multivariable logistic regression model evidenced acceptable calibration (HL goodness-of-fit 
test p=0.13). Following points-conversion, however, the risk score model over- or under-
estimated the probability of ESBL infection at different points along the risk continuum, with 
the exception of very high risk-deciles (HL goodness-of-fit test p-value<0.001) (Supplement 4.2). 
An ESBL-positive cut-point of ≥ 7.25 points maximized overall ESBL-classification accuracy 
(92%). At this cut-off, the risk score had a sensitivity of 49.5% and a specificity of 99.5%, and its 
positive and negative predictive values were 94.6% and 91.8%, respectively. Table 4.1 provides 
the risk score’s sensitivity and specificity at each possible ESBL-positive cut-point.  
 
Decision Tree   
The decision tree using this cohort has been previously described [8] (Figure 4.2). The final tree 
included five predictors: central vascular catheter, age ≥43 years, and in the prior six months: 
history of ESBL colonization/infection, ≥ 1 night hospitalization in an ESBL high-burden region, 
and/or ≥ 1 week of gram-negative active antibiotic therapy. The tree's C-statistic was 0.77 
(unchanged in cross-validation), its sensitivity and specificity were 51.0% and 99.1%, and its 
positive and negative predictive values were 90.8% and 91.9%, respectively. Table 4.2 compares 






Despite advances in rapid diagnostics, timely identification of MDRGNs remains a clinical 
challenge. Diagnostic delays can prolong the period of ineffective antibiotic therapy and also 
increase the risk of nosocomial transmissions [3, 4]. Statistical models for predicting drug 
resistance can play an important role in settings where rapid diagnostic tests are unavailable or 
resource-impractical. This case study of ESBL bloodstream infections explores two approaches 
for developing predictive models: traditional logistic regression-derived risk scores and machine 
learning-derived decision trees.  
 
Given that risk scores for binary predictions are dichotomized at a cut-point, in practice the risk 
score and the decision tree performed similarly: sensitivities 49.5% and 51.0% and specificities 
99.5% and 99.1%, respectively. However, the risk score did possess an approximately 10-
percentage-point higher area-under-the-curve (risk score and decision tree C-statistics: 0.87 vs. 
0.77). This higher AUC offers users more latitude to prioritize sensitivity over specificity, or vice 
versa, by changing the cut-point. It should be noted that, in theory, a decision tree could also be 
developed to optimize a different balance of sensitivity and specificity, but this would require 
deriving an entirely new tree. The risk score’s greater flexibility, however, came at a cost of low 
user-friendliness for manual clinician application. Studies consistently demonstrate that 
incorporating decision support tools at the point of care is important to their success[14], but a 
risk score that requires manual tabulation of 14 variables would encounter significant bedside 




calculations and, at least in this ESBL case study, the final decision tree included far fewer (i.e., 
five) predictors.  
 
The potential tradeoff between flexibility and user-friendliness is one important consideration 
when evaluating whether risk scores or decision trees are a more suitable clinical decision 
support tool for a given application. Additional considerations at various stages of model 
development and implementation, however, may also help to guide clinical researchers in 
selecting one option versus the other. Below, we summarize risk scores’ and decision trees’ 
relative strengths for model development and fitting, implementation, and adaptability. We will 
examine the model algorithm and the outputted model (i.e., clinical decision support tool) in 
parallel because, in practice, this is how most clinical researchers are likely to implement these 
methods. These concepts, however, are not synonymous: CART analysis is the tree-fitting 
process (approach), and a decision tree is the result (output), just as logistic regression is one 
common approach for developing a risk score. Approach and output can differ in their strengths 
and limitations, and we attempt to distinguish these concepts in our discussion where relevant. 
 
Methodological differences between logistic regression and CART influence the data 
assumptions and exploratory analyses required for model development and fitting. In general, 
the more complex or challenging the underlying data, the more utility a machine learning 
approach can provide. Specifically, logistic regression imposes important data requirements, 




ratio of cases-to-predictors (i.e., sufficient sample size; a general, although debatable, guideline 
is 10 expected cases per predictor evaluated) [15, 16]. In contrast, CART is non-parametric and 
makes fewer data assumptions [13], and it can accommodate collinear independent variables. 
It is also less sensitive to outliers and more robust to high-dimensional data, which possess 
many independent variables relative to outcomes. These features are appealing in MDRGN 
clinical research, given the abundance of predictors in patient medical records but relative 
rarity of clinical outcomes. Moreover, logistic regression requires a priori specification and 
evaluation of variable interactions, whereas CART identifies interactions without user input 
[13], a potentially helpful feature where understanding of variable relationships is generally 
limited.  
 
CART’s benefits, however, can come with a steep learning curve for researchers without prior 
experience with these methods. In particular, decision trees are prone to overfitting, in which 
they fit the data “too well” — including its idiosyncrasies and noise — and may consequently 
perform poorly on new data[17]. Sufficient expertise in pruning and/or stopping criteria during 
the tree-branching process is therefore critical to the utility and generalizability of the resulting 
tree, as is use of internal validation methods (e.g., cross-validation) when external testing 
datasets are unavailable. While ensemble tree methods such as random forests analysis can 
address many of these challenges, these methods do not produce a single decision tree that 





Decision trees do not require calculations and are therefore intuitive and generally user-friendly 
for clinicians to apply. Where manual bedside use is anticipated, these features are especially 
beneficial. As facilities incorporate automated decision support tools and algorithms into 
electronic health records (EHRs), these benefits attenuate. Where an automated 
implementation is contemplated, a risk score might be equally easy to use. If automation is 
feasible, however, presumably technical expertise is also readily available, and ensemble 
machine learning algorithms (e.g., random forests or Super Learner) [19, 20] would likely 
outperform both logistic regression and CART (and yield scores or binary predictions as 
preferred). In this ESBL case study, because important variables required clinical judgment (e.g., 
source of infection) or were not hard-coded in the EHR (e.g., foreign country of recent 
hospitalization was only entered as natural language), automating the clinical decision support 
tool would have been challenging. As a result, the decision tree’s simplicity was highly valuable 
for this research application.  
 
Finally, for clinical applications where decision support tool flexibility is paramount, risk scores 
are attractive because their cut-points are modifiable by end-users. Risk scores provide a range 
of score cut-offs, each with an associated sensitivity and specificity, which allow individual users 
to toggle the cut-point in order to minimize the false-positive or false-negative rate (e.g., 
depending upon infection severity or the clinical appearance of the patient). Using the current 
clinical risk score, for example, a user seeking to increase sensitivity could choose a lower cut-
point of ≥ 3 points and reduce the risk of incorrectly classifying an ESBL infection as ESBL-




allows clinicians and hospital epidemiologists to maximize detection of cases, i.e., ESBL-positive 
patients, though at the cost of attendant reductions in specificity and overall classification 
accuracy. We caution, however, that although enhanced flexibility is generally beneficial, a risk 
score’s utility depends upon users understanding the score and the implications of cut-point 
adjustment. Large score differences between patients may translate to minimal differences in 
risk, and vice versa. It is imperative that the table of cut-point sensitivities and specificities 
guides decisions about score thresholds for ESBL infection.  
 
In contrast to risk scores, classification trees provide binary predictions (e.g., “ESBL” or “not 
ESBL”), with a single sensitivity and specificity value for the tree as a whole. Terminal node 
percentages (e.g. “37% probability that ESBL-positive”) can quantify these predictions but do 
not provide a formal mechanism for prioritizing sensitivity versus specificity at earlier points in 
the tree’s branching. For research applications where sensitivity is the priority, methods are 
available to impose a greater “cost” for case misclassification during the tree-fitting process 
[21]. The limitation, however, is that these mechanisms are not adjustable by end-users after a 
tree is built. In other words, while the CART approach provides flexibility to optimize sensitivity 
or specificity, once a single, final tree (output) is developed and provided to clinicians, the 
ability to adjust sensitivity and specificity is limited.  
 
Although the above considerations can help researchers to evaluate whether a risk score or a 




cut. Where each model would at least partially meet stated goals, we encourage investigators 
to develop both support tools in parallel in order to compare their performance metrics. In 
particular, although model performance was comparable in this case study, other applications 
with more challenging data (e.g., high-dimensionality, higher-order variable interactions) might 
more clearly favor a machine learning approach such as CART. 
 
A hybrid analysis that combines methodological strengths — e.g., aspects of one approach with 
the output of the other — should also be considered. For example, even where a risk score is 
the optimal output, ensemble tree methods can rank the most predictive variables to compare 
to the variables retained in stepwise regression [18, 19]; preliminary data analysis with CART 
can also identify potentially meaningful variable interactions for modeling interaction terms 
during regression model development. Conversely, researchers fitting decision trees might still 
consider supplemental regression analysis if, for example, ascertainment of “independent” 
variables is important for generating causal hypotheses. Because most decision tree algorithms 
optimize predictive accuracy, variables retained in decision trees can be arbitrary among 
collinear predictors, and they do not necessarily reflect independent exposures [22]. 
 
Our study has several limitations. It was a single-center study, and although we internally 
validated our models, it lacked an external validation cohort. In addition, there was the 
potential for missing data in patients treated outside of the Epic Care Everywhere network, 




misclassification would likely reduce predictive performance, and yet risk score discrimination 
remained robust. Nevertheless, we would encourage future evaluation of the risk score in other 
cohorts. Importantly, however, because study characteristics were constant across analyses, we 
expect decision tree and risk score comparisons to be unbiased.  
  
Overall, timely identification of MDRGN infections remains a clinical and epidemiological 
challenge. Rapid detection enables isolation of infected patients and prompt initiation of 
appropriate antibiotic treatment. Statistical models for predicting drug resistance can provide 
important information in settings where laboratory diagnostics are challenging to implement. 
This examination explored two alternative decision support tools, logistic regression-derived 
risk scores and machine learning-derived decision trees, in an inpatient cohort of bacteremic 
patients in order to predict ESBL infection. These methodologies offer different strengths and 
limitations, and we hope that their continued utilization in clinical infectious disease research 
will assist with improving patient outcomes.  
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Table 4.1.  Risk Score Sensitivity, Specificity, and Overall Classification Accuracy at Select Cut-
points for Predicting Extended-Spectrum β-Lactamase (ESBL) Status in a Cohort of Adult 
Patients with Escherichia coli and Klebsiella Species Bacteremia* 
Risk Score Cut-
point 
Sensitivity Specificity Percent of 
Observations Correctly 
Classified 
 ≥ 0  100.0% 0.7% 15.7% 
 ≥ .25  95.4% 31.5% 41.2% 
 ≥ .5  94.9% 35.7% 44.6% 
 ≥ .75  93.8% 37.0% 45.6% 
 ≥ 1  93.3% 38.8% 47.0% 
 ≥ 1.25  90.7% 51.3% 57.2% 
 ≥ 1.5  89.7% 54.1% 59.5% 
 ≥ 1.75  89.2% 55.6% 60.6% 
 ≥ 2  88.7% 56.7% 61.5% 
 ≥ 2.25  85.6% 70.2% 72.5% 
 ≥ 2.5  84.0% 71.6% 73.5% 
 ≥ 2.75  83.5% 72.5% 74.2% 
 ≥ 3  83.5% 73.1% 74.7% 
 ≥ 3.25  77.8% 83.4% 82.5% 
 ≥ 3.5  74.2% 86.8% 84.9% 
 ≥ 3.75  71.7% 87.7% 85.3% 
 ≥ 4  70.6% 88.3% 85.6% 
 ≥ 4.25  65.5% 92.6% 88.5% 
 ≥ 4.5  64.4% 92.8% 88.5% 
 ≥ 4.75  63.9% 93.2% 88.8% 
 ≥ 5  63.9% 93.4% 89.0% 
 ≥ 5.25  61.9% 95.7% 90.6% 




 ≥ 5.75  60.8% 96.6% 91.2% 
 ≥ 6  60.8% 97.0% 91.5% 
 ≥ 6.25  55.2% 98.2% 91.7% 
 ≥ 6.5  54.6% 98.4% 91.8% 
 ≥ 6.75  54.6% 98.5% 91.9% 
 ≥ 7  54.1% 98.5% 91.9% 
 ≥ 7.25  49.5% 99.5% 91.9% 
 ≥ 7.5  46.9% 99.5% 91.5% 
 ≥ 7.75  46.4% 99.5% 91.5% 
 ≥ 8  45.9% 99.5% 91.4% 
 ≥ 8.25  40.2% 99.5% 90.6% 
 ≥ 8.5  38.7% 99.7% 90.5% 
 ≥ 8.75  38.1% 99.8% 90.5% 
 ≥ 9  37.6% 99.8% 90.5% 
 ≥ 9.25  31.4% 100.0% 89.7% 
 
* Cut-points < 0 and ≥ 9.5 were excluded because, respectively, they yielded equal sensitivity 
(100%) but inferior specificity, or inferior sensitivity but equal specificity (100%). Dark gray 





Table 4.2.  Comparative Performance Metrics of a Logistic Regression-Derived Clinical Risk 
Score and a Machine Learning-Derived Decision Tree to Predict Extended-Spectrum β-
Lactamase (ESBL) Status 
 Risk Score Decision Tree 
No. of Included Variables 14 5 
Sensitivitya 49.5% 51.0% 
Specificitya 99.5% 99.1% 
Positive Predictive Value (PPV)a 94.6% 90.8% 
Negative Predictive Value (NPV)a 91.8% 91.9% 
Naïve C-Statistic 0.87 0.77 
Cross-Validated C-Statistic 0.89 0.77 
 
a Risk score values vary depending upon the selected cut-point for dichotomization. Values 
reflected for the risk score are for the cut-point of ≥ 7.25 points, which optimized overall 





Table 4.3.  Comparative Strengths and Limitations of Logistic Regression-Derived Risk Scores 
and Classification and Regression Tree (CART) Analysis-Derived Decision Trees for Predicting 








   
High-
Dimensionality 
- +++ Decision trees are well-suited to high-dimensional 
data, which possess high predictor-to-outcome 
ratios. Logistic regression-derived risk scores 
impose more stringent sample size requirements 
(a general requirement is 10 expected cases per 
predictor). 
Collinearity - +++ Logistic regression-derived risk scores require 
minimal collinearity among independent variables, 
unlike decision trees. 
Interaction 
Effects 
+ +++ Logistic regression can accommodate interaction 
effects, but it requires moderately large sample 
sizes and a priori evaluation. CART decision trees 
can detect simple and higher-level interaction 
effects without user specification. 
Rare Outcome(s) + + Rare outcomes pose challenges for both models. In 
logistic regression, rare outcomes limit the number 
of evaluable predictors. CART analysis may require 
parameter adjustment and/or case over-sampling 
before model fitting and validation in order to 
improve sensitivity if outcomes are rare. 
Model 
Development 
   
Ease-of-
Development  
++ + Decision trees for standard applications are 
relatively straightforward to develop, but logistic 
regression-derived risk score methodology is more 
well-known in the clinical infectious disease 
literature and more widely available on all 
common statistical computing platforms. 
Robustness to 
Overfitting 
++ - Both methods require validation, but decision 
trees are particularly prone to overfitting, in which 




perform poorly on new data. Methods to combat 
overfitting include imposing branching-stop 
criteria and “pruning” back terminal branches. 
Implementation 
& Usage 
   
Intuitiveness + +++ Decision tree branching logic is highly intuitive. 
Ease-of-Use + +++ Decision trees do not require calculations, making 
them very user-friendly for bedside application. 





+++ - By changing the score cut-point, individual users 
can tailor risk scores’ sensitivity and specificity. A 
decision tree possesses a fixed sensitivity and 
specificity that, following model development, 
cannot be modified.  
Addition of New 
Variables Over 
Time 
++ + New variable(s) can be evaluated for risk score 
inclusion (e.g., by comparing Akaike’s Information 
Criterion (AIC) values of the original and expanded 
models)[1]. Variable addition may change 
coefficient values and, accordingly, risk score 
points, but will leave original score variables intact. 
Because decision trees are built “top-down,” new 
variables require tree refitting and may 





Figure 4.1. A printable clinical risk score for bedside use to predict a bacteremic patient's 
likelihood of infection with an extended-spectrum β-lactamase (ESBL)–producing organism at 
the time of organism genus and species identification. Risk factor points are noted in 
parentheses and summed among the 14 variables to produce a patient’s risk score. Possible 
score cut-offs for ESBL-positive bacteremia, and associated sensitivities and specificities, are 
reflected in Table 4.1. 
 




bLatin America (excluding the Caribbean), the Middle East (including Egypt), South Asia, China, 
and the Mediterranean. 
*This statement reflects the positive predictive value of the score at a cut-point of 7.25 points 
and should be modified by the facility to account for local prevalence of ESBL bacteremia. 
Abbreviations: MDRGN – Multidrug-resistant Gram-negative organism; CRE – Carbapenem-
resistant Enterobacteriaceae; MDR – Multidrug-resistant. Drug-resistant organisms defined in 






Figure 4.2.  A clinical decision tree to predict a bacteremic patient's likelihood of infection 
with an extended-spectrum β-lactamase (ESBL)–producing organism at the time of organism 
genus and species identification, adapted from Goodman et al., 2016[3]. Gray-shaded 
terminal nodes indicate that the tree would classify patients as ESBL positive, and 
accompanying percentages (derived from terminal node impurities) reflect the probability that 
patients assigned to a given terminal node are ESBL-positive. Terminal node numbering (1–6) is 
included in parentheses.  
 
 
*Latin America (excluding the Caribbean), the Middle East (including Egypt), South Asia, China, 





SUPPLEMENTAL MATERIAL, SECTION 4: 
 
Supplemental Figure S.4.1. Receiver operating characteristic (ROC) curve for the logistic 
regression model, prior to risk score transformation. Area under the curve (AUC), after 








Supplemental Figure S.4.2.  Calibration plot of observed proportion versus model-predicted 
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5.  CONCLUSION 
5.1. Summary of Findings 
 
Carbapenem-resistant Enterobacteriaceae (CRE) and other carbapenem-resistant organisms 
(CROs) pose important and increasingly urgent challenges to patient care. These bacteria are 
resistant to nearly all routinely used antibiotics and can impose mortality rates approaching 50 
percent [1]. Of particular concern are the subset of CROs that are carbapenamase-producing 
(CPOs), for which carbapenem resistance is generally plasmid-mediated and can transfer 
between organisms. Carbapenemase genes have become established in some bacterial strains 
that are highly adept at clonal expansion, and CPOs have been implicated in numerous 
outbreaks in U.S. healthcare facilities [2].   
 
Current prevention strategies for CROs and CPOs in healthcare facilities include efforts to 
reduce selective pressure from antibiotic exposure, e.g., antibiotic stewardship programs, and 
infection control policies to reduce patient-to-patient spread following resistance emergence or 
CRO/CPO introduction (e.g., active surveillance for CRO carriage at admission and placing 
colonized patients on contact precautions). These efforts are hampered by a lack of rapid and 
cost-effective diagnostics to identify CROs, CPOs, and other MDRGNs. We aimed to develop 






In Aim 1, we screened nearly 3,000 patients admitted to the Johns Hopkins Hospital (JHH) 
medical intensive care unit (MICU) and comprehensive transplant unit (Transplant Unit) for 
perirectal colonization with CROs and CPOs. We found that 7.5% and 1.3% of patients were 
perirectally colonized with CROs and CPOs, respectively, and estimated a CRE admission 
prevalence of 4.2% (95% CI: 3.5 – 5.0%). We further tested all CPO isolates to reveal a diversity 
of carbapenemase gene-organism pairs. These data add important information to the 
epidemiological landscape of asymptomatic CRO and CPO carriage in U.S. inpatient populations. 
We collected comprehensive data (> 150 variables) on patient pre-admission exposures 
through automated extraction from electronic medical records (EMRs). These data were used 
to evaluate risk factors for colonization and to develop machine learning-derived predictive 
models to inform targeted screening. We identified a large number of variables significantly 
associated with colonization, many of which are consistent with published literature for CRO 
infection or for CRO colonization in other populations and settings. Despite this large number of 
significant variables, however, our models did not highly predict colonization, primarily due to 
low sensitivity. We were, however, able to identify specific high-risk sub-groups (e.g., patients 
with a recent CRO history and extended proton-pump inhibitor use). Our experience also 
yielded insights that may be informative to future research, including the role of heterogeneity 
in prediction models and differences between causal risk factors and predictors.  
 
In Aim 2, we developed a clinical decision tree to predict infection with an extended-spectrum 
β-lactamase (ESBL)–producing organism, in order to reduce unnecessary carbapenem 




October 2008 and March 2015 with bacteremia due to Escherichia coli or Klebsiella species. We 
collected pre-infection clinical and demographic information through manual chart review and 
used recursive partitioning to generate a decision tree to determine the likelihood that a 
bacteremic patient was infected with an ESBL-producer. The final classification tree for 
predicting ESBL-positive bacteremia included 5 predictors: history of ESBL 
colonization/infection, chronic indwelling vascular hardware, age ≥43 years, recent 
hospitalization in an ESBL high-burden region, and ≥6 days of antibiotic exposure in the prior 6 
months. The decision tree's area under the curve (AUC) was 0.77 and unchanged in cross-
validation, and its positive and negative predictive values were 90.8% and 91.9%, respectively. 
Our findings demonstrated that a user-friendly decision tree can reliably discriminate between 
ESBL-positive and –negative infections at the time of empirical treatment initiation in order to 
inform appropriate carbapenem usage. 
 
In Aim 3, we developed a clinical risk score from the same ESBL dataset as Aim 2 in order to 
methodologically compare decision trees versus risk scores for predicting drug-resistant 
colonization or infection. The final clinical risk score for predicting ESBL-positive bloodstream 
infection at the time of organism and genus identification included 14 variables, broadly 
categorizable into six groups: Indwelling hardware on day of culture; presumptive source of 
bloodstream infection; patient characteristics; and, within the previous six months: healthcare 
exposure, MDRGN colonization or infection, or antibiotic usage. The risk score possessed higher 
discrimination than the decision tree (risk score C-statistic 0.87), but given that risk scores for 




tree performed similarly. However, with 14 variables, the risk score was less amenable to 
manual bedside use. In our discussion, we reviewed practical and methodological attributes of 
decision trees and risk scores and offered general guiding principles for when clinicians or 
hospital epidemiologists might consider each approach. We intended this examination to be 
highly practical and easily accessible, and believe that it addressed an unmet need in the clinical 
infectious disease and healthcare epidemiology literature. 
 
5.2. Strengths and Limitations 
Our studies had several strengths. The most important strength of Aims 1 and 2 (and Aim 3, by 
corollary) were our study populations and sample sizes. Aim 1’s prospective cohort included 
thousands of patients, enabling robust colonization estimates despite outcome rarity, including 
stratified by bacterial class and resistance mechanism. The study also strongly benefitted from 
its ability to capitalize on an existing, longstanding VRE surveillance program. This infrastructure 
helped to maximize screening compliance and, in practice, made the study feasible. Without an 
existing program, individual informed consent would have been required, potentially biasing 
resulting estimates (e.g., sicker patients, such as those on ventilators, could be differentially 
excluded due to inability to consent). Similarly, to our knowledge Aim 2’s retrospective cohort 
of 1,288 patients represents the largest existing cohort to examine risk factors and predictors 
for ESBL-positive bacteremia. Further, all aims benefitted from extensive clinical and 
demographic data collection, through a variety of both manual and automated methods, and 
built on the strengths of established clinical and molecular microbiology laboratories in order to 




methodology not routinely used in the infection control and clinical infectious disease 
literature. These approaches are methodologically well-suited to the high-dimensional data 
present in these aims, and decision trees in particular have practical advantages, including 
simplicity and intuitive interpretation.    
 
Our studies also had several limitations. All aims involved single-center studies, and although 
we internally validated our models, our results should be validated in other cohorts. Our results 
may not be generalizable to other, in particular lower risk, patient populations. Aim 1 also had 
missing swabs for some unit admissions, although through the collective efforts of weekly real-
time audits and floor re-education campaigns we were able to reduce missingness to less than 
15 percent across the study period. Moreover, despite our best attempt to gather detailed 
previous clinical and demographic data on all patients, we were limited to Johns Hopkins 
Healthcare system (Aim 1) or Epic Care Everywhere (Aims 2 and 3) data. There was likely 
missing data on pre-admission or pre-infection exposures that could lead to exposure 
misclassification. Nevertheless, because of our prediction models’ intended real-world use, 
their performance under the practical constraints of missing data was arguably relevant. As the 
use of electronic health records that interface across institutions becomes more widespread, 
these challenges will hopefully lessen. Finally, all of our tree-based predictive models 
demonstrated, to varying degrees, sub-optimal sensitivity. Because risk factor associations in 
our both our colonization and infection studies were numerous and strong, but sensitivity was 
very poor for specific sub-populations, we believe that these patient subsets may lack 




exposures would not be captured in medical records. Due to our study designs (de-linked 
patient identifiers in Aim 1 and a retrospective cohort in Aim 2), we were unable to explore 
these hypotheses further.  
 
5.3. Public Health Implications and Recommendations for Future Research 
In the U.S., CRO and CPO infections remain rare but devastating. Efforts to reduce carbapenem 
resistance in healthcare settings must maximize patient safety while simultaneously ensuring 
that policies are cost-effective and implementable. A lack of rapid, inexpensive microbiological 
diagnostics for many MDRGNs adds considerably to this challenge.  
 
Our findings suggest that asymptomatic CRO and CPO carriage is infrequent among high-risk 
hospitalized patients, but nevertheless higher than the limited other published estimates 
available. With our data indicating that 1 of every 10 – 15 patients silently brings carbapenem-
resistant bacteria into the ICU, the risk to other patients is potentially substantial. However, 
colonized patients’ contribution to CRO spread once they enter hospital units remains poorly 
quantified. Despite circumstantial evidence linking CPOs to healthcare-associated outbreaks, it 
is also remains unknown whether propensity for intra-facility spread systematically differs 
between CROs and CPOS. These questions remain pressing as long as universal CRO screening 
remains impractical and accurate targeted screening algorithms are unavailable. Future 
research addressing these knowledge gaps is critical to ensure that policies target the highest-




and to the environment. Our Aim 1 study included weekly surveillance swabs, and we plan to 
investigate these questions in subsequent analyses.  
 
We were unfortunately unable to develop highly predictive, targeted screening algorithms for 
CRO and CPO colonization despite extensive data collection on pre-admission risk factors. An 
important goal of artificial intelligence and other machine learning applications in healthcare is 
to capitalize on an abundance of ‘Big Data,’ despite its imperfections, to improve patient 
outcomes. This was a pragmatic study which demonstrated that the data currently available to 
us in the EMR, as extracted, did not meet these targets. Ongoing research and efforts to refine 
where, how, and which data we utilize will be important.  
 
Notwithstanding these challenges, our results offer some actionable conclusions. A recent CRO- 
or CRE-positive culture was consistently the strongest predictor of colonization at admission, 
and many infection control programs already capture and flag these cultures. As such, existing 
policies — however imperfect — may be performing equivalently to a targeted screening 
program. Moreover, a sizable percentage of CRO- and CPO-colonized patients were co-
colonized with VRE detected during routine admission screening. These patients would be 
placed on contact precautions even without dedicated CRO surveillance. These findings suggest 
that existing screening policies for other organisms may have unrecognized, off-target benefits, 




VRE rectal surveillance [3]. Cost-benefit analyses that account for these effects may be useful 
future investigations.  
 
Finally and more generally, across our studies we encountered similar recurring challenges 
when developing prediction models for drug-resistant colonization or infection. Two of the 
most detrimental elements were outcome rarity, which compromised sensitivity in 
classification algorithms, and high heterogeneity or stochasticity underlying the biological 
process of acquisition or infection. As such, even strong risk factors accounted for only small 
absolute numbers of cases. Methodologically, we believe these findings would benefit from 
formal simulation studies in order to further dissect differences between risk factors and 
predictors and to better understand how to optimize EMR data retrieval when designing large, 
hospital-based cohort studies.  
 
Practically, these findings also shed light on potential future model applications. In particular, 
although these limitations are likely to persist in U.S. patient populations, international, low-
resource countries (e.g., India) generally have much higher CRO and CPO prevalence [4]. With a 
high proportion of community acquisition, they may also have more easily identifiable 
colonization or infection predictors (at least proportionally, although we note that EMR data is 
likely far more limited). Moreover, even as diagnostic improvements ease prediction challenges 
in the U.S., rapid molecular assays will remain cost-prohibitive for large scale screening in 




statistical models for predicting drug-resistant bacterial colonization or infection may achieve 
greater accuracy, and meet more pressing healthcare needs, in non-U.S. settings with higher 
prevalence. In both domestic and international settings, however, statistical models will 
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